| 公司 | 年份 | 百万美元 | 较上年变化,% | 等级 | 报告值 | 来源 | 位置 | 备注 |
|---|---|---|---|---|---|---|---|---|
| argenx | 2025 | 4151 | – | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| BioNTech | 2022 | 3339 | – | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| CJ第一制糖 | 2015 | 3228 | – | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CJ CheilJedang ... 3,228" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| CSL | 2000 | 582 | – | C | 1,000 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2001 | 620 | 6.7 | C | 1,200 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2002 | 761 | 22.7 | C | 1,400 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2003 | 1109 | 45.7 | C | 1,700 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2004 | 1326 | 19.6 | C | 1,800 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2005 | 1525 | 15.0 | C | 2,000 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2006 | 1658 | 8.7 | C | 2,200 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2007 | 2097 | 26.5 | C | 2,500 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2008 | 2642 | 26.0 | C | 3,100 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2009 | 3248 | 22.9 | C | 4,100 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2010 | 4050 | 24.7 | C | 4,400 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4400 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2011 | 4751 | 17.3 | C | 4,600 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4600 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2012 | 5181 | 9.0 | C | 5,000 AUD m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (plasma/vaccines pure-play biopharma)Total revenue (plasma/vaccines pure-play biopharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5000 AUD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| CSL | 2013 | 4875 | -5.9 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 4,875" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| CSL | 2014 | 4743 | -2.7 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 4,743" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| CSL | 2015 | 6294 | 32.7 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 6,294" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| CSL | 2016 | 6674 | 6.0 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 6,674" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| CSL | 2017 | 7522 | 12.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 7,522" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| CSL | 2018 | 8270 | 9.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 8,270" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| CSL | 2019 | 8951 | 8.2 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"CSL ... 8,951" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| CSL | 2020 | 9656 | 7.9 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| CSL | 2021 | 10444 | 8.2 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| CSL | 2022 | 13123 | 25.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| CSL | 2023 | 14176 | 8.0 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| CSL | 2024 | 15009 | 5.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| CSL | 2025 | 15441 | 2.9 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| Horizon Therapeutics | 2022 | 4022 | – | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| Novavax | 2022 | 1555 | – | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 三共 | 2004 | 4051 | – | B | 435,140 JPY m | phx_dsc_pres+phx_daiichi_20f+fx_fed_h10 | Daiichi Sankyo merger presentation, FY2004 combined pharma figure | Pharmaceutical net sales: combined Sankyo + Daiichi Pharm...Pharmaceutical net sales: combined Sankyo + Daiichi Pharmaceutical (760 bn yen) minus Daiichi Pharmaceutical (324.9 bn)760,000 - 324,860 = 435,140; Sankyo total net sales 587,830 incl. non-pharma The 760 bn combined figure was quoted in a search result for a Daiichi Sankyo investor presentation; document not opened. |
| 三菱化学集团 | 2023 | 4235 | – | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 上海医药 | 2000 | 83 | – | C | 690 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2000-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 460,072.38" (10,000 CNY) = 4,600.72 m x 15% = 690.11 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2001 | 94 | 13.3 | C | 782 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2001-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 521,059.32" (10,000 CNY) = 5,210.59 m x 15% = 781.59 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2002 | 131 | 39.1 | C | 1,088 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2002-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 725,045.56" (10,000 CNY) = 7,250.46 m x 15% = 1,087.57 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2003 | 178 | 35.2 | C | 1,470 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2003-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 980,255.52" (10,000 CNY) = 9,802.56 m x 15% = 1,470.38 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2004 | 197 | 10.6 | C | 1,627 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2004-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 1,084,383.04" (10,000 CNY) = 10,843.83 m x 15% = 1,626.57 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2005 | 196 | -0.1 | C | 1,608 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2005-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 1,072,286.69" (10,000 CNY) = 10,722.87 m x 15% = 1,608.43 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2006 | 238 | 21.1 | C | 1,896 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2006-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 1,263,916.73" (10,000 CNY) = 12,639.17 m x 15% = 1,895.88 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2007 | 275 | 15.5 | C | 2,088 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2007-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 1,391,979.12" (10,000 CNY) = 13,919.79 m x 15% = 2,087.97 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2008 | 357 | 30.1 | C | 2,482 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2008-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 1,654,782.49" (10,000 CNY) = 16,547.82 m x 15% = 2,482.17 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2009 | 430 | 20.2 | C | 2,935 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2009-12-31 | Pharmaceutical industry arm estimated as 15% of consolida...Pharmaceutical industry arm estimated as 15% of consolidated revenue (distribution excluded)"营业收入 1,956,812.38" (10,000 CNY) = 19,568.12 m x 15% = 2,935.22 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2010 | 663 | 54.4 | C | 4,489 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2010-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 3,741,106.61" (10,000 CNY) = 37,411.07 m x 12% = 4,489.33 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2011 | 1019 | 53.7 | C | 6,588 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2011-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 5,489,987.25" (10,000 CNY) = 54,899.87 m x 12% = 6,587.98 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2012 | 1295 | 27.0 | C | 8,169 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2012-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 6,807,811.78" (10,000 CNY) = 68,078.12 m x 12% = 8,169.37 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2013 | 1527 | 17.9 | C | 9,387 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2013-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 7,822,281.74" (10,000 CNY) = 78,222.82 m x 12% = 9,386.74 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2014 | 1800 | 17.9 | C | 11,088 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2014-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 9,239,889.36" (10,000 CNY) = 92,398.89 m x 12% = 11,087.87 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2015 | 2016 | 12.0 | C | 12,662 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2015-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 10,551,658.73" (10,000 CNY) = 105,516.59 m x 12% = 12,661.99 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2016 | 2183 | 8.3 | C | 14,492 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2016-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 12,076,466.03" (10,000 CNY) = 120,764.66 m x 12% = 14,491.76 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2017 | 2325 | 6.5 | C | 15,702 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2017-12-31 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)"营业收入 13,084,718.19" (10,000 CNY) = 130,847.18 m x 12% = 15,701.66 m Shanghai Pharmaceuticals is about 85-90% distribution and retail; the 2019 Pharm Exec row (US$ 2,875 m, about RMB 19.8 bn) is its industrial arm, so industry is estimated. Anchors: Q1 2017 industry revenue RMB 3.79 bn and 9M 2017 about 11.15 bn (broker notes via search; FY2017 about 15 bn = 11.6% of 130.8 bn). Pre-2010 company (old 600849) was distribution-led; 15% assumed. Replace with annual-report industry segment figures when read. |
| 上海医药 | 2018 | 2891 | 24.4 | C | 19,090 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)1590.84亿 total x 12% = 19090.1 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 上海医药 | 2019 | 2875 | -0.6 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shanghai Pharmaceuticals Holding ... 2,875" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 上海医药 | 2020 | 3340 | 16.2 | C | 23,029 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)1919.09亿 total x 12% = 23029.1 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 上海医药 | 2021 | 4016 | 20.2 | C | 25,899 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)2158.24亿 total x 12% = 25898.9 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 上海医药 | 2022 | 4144 | 3.2 | C | 27,838 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)2319.81亿 total x 12% = 27837.7 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 上海医药 | 2023 | 4415 | 6.5 | C | 31,235 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)2602.95亿 total x 12% = 31235.4 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 上海医药 | 2024 | 4591 | 4.0 | C | 33,030 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)2752.51亿 total x 12% = 33030.1 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 上海医药 | 2025 | 4735 | 3.1 | C | 34,030 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical industry arm estimated as 12% of consolida...Pharmaceutical industry arm estimated as 12% of consolidated revenue (distribution excluded)2835.80亿 total x 12% = 34029.6 RMB m Same estimate as 2012-2017: 12% of consolidated revenue; share not verified for later years (grade C) |
| 东阿阿胶 | 2000 | 49 | – | B | 406 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 40,637.05" (10,000 CNY) = 406.37 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2001 | 55 | 11.4 | B | 453 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 45,266.70" (10,000 CNY) = 452.67 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2002 | 69 | 26.1 | B | 571 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 57,059.66" (10,000 CNY) = 570.60 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2003 | 90 | 31.2 | B | 748 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 74,839.77" (10,000 CNY) = 748.40 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2004 | 107 | 18.0 | B | 883 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 88,295.38" (10,000 CNY) = 882.95 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2005 | 115 | 7.6 | B | 941 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 94,053.82" (10,000 CNY) = 940.54 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2006 | 135 | 17.2 | B | 1,073 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"主营业务收入 107,291.00" (10,000 CNY) = 1,072.91 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2007 | 182 | 35.0 | B | 1,381 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 138,136.07" (10,000 CNY) = 1,381.36 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2008 | 243 | 33.6 | B | 1,686 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 168,595.53" (10,000 CNY) = 1,685.96 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2009 | 304 | 25.4 | B | 2,079 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 207,910.61" (10,000 CNY) = 2,079.11 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2010 | 364 | 19.6 | B | 2,464 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 246,378.43" (10,000 CNY) = 2,463.78 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2011 | 427 | 17.3 | B | 2,759 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 275,884.83" (10,000 CNY) = 2,758.85 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2012 | 484 | 13.5 | B | 3,056 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 305,607.43" (10,000 CNY) = 3,056.07 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2013 | 653 | 34.9 | B | 4,016 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 401,630.44" (10,000 CNY) = 4,016.30 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2014 | 651 | -0.4 | B | 4,009 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 400,901.05" (10,000 CNY) = 4,009.01 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2015 | 868 | 33.3 | B | 5,450 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 544,966.32" (10,000 CNY) = 5,449.66 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2016 | 951 | 9.7 | B | 6,317 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 631,713.53" (10,000 CNY) = 6,317.14 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2017 | 1092 | 14.7 | B | 7,372 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入/营业收入 737,234.03" (10,000 CNY) = 7,372.34 m Sina Finance table for stock 000423. |
| 东阿阿胶 | 2018 | 1111 | 1.8 | B | 7,338 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 73.38亿元" = 7338 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 东阿阿胶 | 2019 | 430 | -61.3 | B | 2,970 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 29.70亿元" = 2970 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table; 2019 drop reflects the sharp fall in sales (channel destocking) |
| 东阿阿胶 | 2020 | 494 | 14.9 | B | 3,409 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 34.09亿元" = 3409 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 东阿阿胶 | 2021 | 597 | 20.7 | B | 3,849 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 38.49亿元" = 3849 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 东阿阿胶 | 2022 | 602 | 0.8 | B | 4,042 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 40.42亿元" = 4042 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 东阿阿胶 | 2023 | 666 | 10.7 | B | 4,715 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 47.15亿元" = 4715 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 东阿阿胶 | 2024 | 856 | 28.4 | B | 6,157 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 61.57亿元" = 6157 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 东阿阿胶 | 2025 | 932 | 8.9 | B | 6,700 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Shandong Dong-E E-Jia...Total revenue of the listed company Shandong Dong-E E-Jiao (donkey-hide gelatin, TCM)"营业总收入 67.00亿元" = 6700 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 中国生物制药 | 2002 | 44 | – | B | 343 HKD m | phx_cn_sino_ar06+fx_fed_h10 | Five-year financial summary (read through a search snippet; column order inferred) | Turnover (pharmaceutical)Turnover (pharmaceutical)same table Continuing operations only (earlier businesses discontinued); HK$. |
| 中国生物制药 | 2003 | 59 | 33.3 | B | 456 HKD m | phx_cn_sino_ar06+fx_fed_h10 | Five-year financial summary (read through a search snippet; column order inferred) | Turnover (pharmaceutical)Turnover (pharmaceutical)same table Continuing operations only (earlier businesses discontinued); HK$. |
| 中国生物制药 | 2004 | 85 | 45.6 | B | 664 HKD m | phx_cn_sino_ar06+fx_fed_h10 | Five-year financial summary (read through a search snippet; column order inferred) | Turnover (pharmaceutical)Turnover (pharmaceutical)same table Continuing operations only (earlier businesses discontinued); HK$. |
| 中国生物制药 | 2005 | 97 | 14.0 | B | 756 HKD m | phx_cn_sino_ar06+fx_fed_h10 | Five-year financial summary (read through a search snippet; column order inferred) | Turnover (pharmaceutical)Turnover (pharmaceutical)same table Continuing operations only (earlier businesses discontinued); HK$. |
| 中国生物制药 | 2006 | 95 | -2.7 | B | 735 HKD m | phx_cn_sino_ar06+fx_fed_h10 | Five-year financial summary (read through a search snippet; column order inferred) | Turnover (pharmaceutical)Turnover (pharmaceutical)2006 Annual Report five-year summary, continuing operations: 734,652 756,073 664,296 456,089 342,610 (HK$'000; order assumed 2006 to 2002, from the 2005 report chart showing 2003 = 456,089 and 2004 = 664,296) Continuing operations only (earlier businesses discontinued); HK$. |
| 中国生物制药 | 2007 | 149 | 57.8 | C | 1,164 HKD m | phx_sinobio_hkex+fx_fed_h10 | 2008 results announcement: 2008 turnover +96% | Turnover (pharmaceutical)Turnover (pharmaceutical)2,282.21 / 1.96 = 1,164.4 Back-calculated from the stated growth of about 96% in 2008; no 2007 figure read directly. |
| 中国生物制药 | 2012 | 966 | – | B | 7,497 HKD m | phx_cn_sino_ar14+fx_fed_h10 | Financial Summary (read via pdftotext) | Turnover (pharmaceutical)Turnover (pharmaceutical)2014 AR Financial Summary: TURNOVER 12,378,350 9,901,196 7,496,888 5,171,354 3,618,773 (HK$'000, 2014 to 2010) HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported. |
| 中国生物制药 | 2013 | 1277 | 32.1 | B | 9,901 HKD m | phx_cn_sino_ar14+fx_fed_h10 | Financial Summary (read via pdftotext) | Turnover (pharmaceutical)Turnover (pharmaceutical)same table: 9,901,196 HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported. |
| 中国生物制药 | 2014 | 1596 | 25.1 | B | 12,378 HKD m | phx_cn_sino_ar14+fx_fed_h10 | Financial Summary (read via pdftotext) | Turnover (pharmaceutical)Turnover (pharmaceutical)same table: 12,378,350 HK$ reporting currency. The same table restates 2010-2011 (3,618.8 and 5,171.4) below the earlier rows (4,086 and 5,782, as first reported) after a disposal; 2012 onward as reported. |
| 中国生物制药 | 2015 | 1877 | 17.6 | B | 14,550 HKD m | phx_cn_sino_res15+fx_fed_h10 | Management discussion, revenue paragraph | Turnover (pharmaceutical)Turnover (pharmaceutical)The Group recorded revenue of approximately HK$14,550.23 million HK$ reporting currency. |
| 中国生物制药 | 2016 | 2039 | 8.6 | B | 15,825 HKD m | phx_cn_sino_res16+fx_fed_h10 | Management discussion, revenue paragraph | Turnover (pharmaceutical)Turnover (pharmaceutical)The Group recorded revenue of approximately HK$15,825.44 million Last year in HK$; from FY2017 the group reports in RMB. |
| 中国生物制药 | 2017 | 2194 | 7.6 | B | 14,819 CNY m | phx_cn_sino_res17+fx_fed_h10 | Financial highlights (b) | Turnover (pharmaceutical)Turnover (pharmaceutical)revenue of approximately RMB14,819.30 million, +9.4% RMB from FY2017 (checked in the document); earlier rows are HK$. |
| 中国生物制药 | 2018 | 3142 | 43.2 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sino Biopharm ... 3,142" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 中国生物制药 | 2019 | 3373 | 7.4 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sino Biopharmaceutical ... 3,373" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 中国生物制药 | 2020 | 3430 | 1.7 | B | 23,647 CNY m | phx_cn_sino_res+fx_fed_h10 | results / financials table | Turnover (pharmaceutical)Turnover (pharmaceutical)"Revenue RMB23,647.22 million, -2.4%" RMB; continuing-operations basis as reported in each year |
| 中国生物制药 | 2021 | 4165 | 21.4 | B | 26,861 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Turnover (pharmaceutical)Turnover (pharmaceutical)FY2021 26,861 RMB; continuing-operations basis as reported in each year |
| 中国生物制药 | 2022 | 3875 | -7.0 | B | 26,026 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Turnover (pharmaceutical)Turnover (pharmaceutical)FY2022 26,026 RMB; continuing-operations basis as reported in each year |
| 中国生物制药 | 2023 | 3703 | -4.4 | B | 26,199 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Turnover (pharmaceutical)Turnover (pharmaceutical)FY2023 26,199 RMB; continuing-operations basis as reported in each year |
| 中国生物制药 | 2024 | 4012 | 8.3 | B | 28,866 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Turnover (pharmaceutical)Turnover (pharmaceutical)FY2024 28,866 RMB; continuing-operations basis as reported in each year |
| 中国生物制药 | 2025 | 4429 | 10.4 | B | 31,834 CNY m | phx_cn_sino_res+fx_fed_h10 | results / financials table | Turnover (pharmaceutical)Turnover (pharmaceutical)"Revenue 31.83 bn (2025) vs 28.87 bn (2024), +10.3%" RMB; continuing-operations basis as reported in each year |
| 中外制药 | 2001 | 1695 | – | B | 211,700 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 211,700 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2003 | 2010 | – | B | 232,700 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 232,700 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2004 | 2726 | 35.6 | B | 294,670 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 294,670 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2005 | 2976 | 9.2 | B | 327,155 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 327,155 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2006 | 2803 | -5.8 | B | 326,109 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 326,109 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2007 | 2931 | 4.5 | B | 344,808 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 344,808 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2008 | 3171 | 8.2 | B | 326,937 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 326,937 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2009 | 4588 | 44.7 | B | 428,947 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 428,947 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). 2009 includes the Tamiflu stockpiling boom. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2010 | 4334 | -5.6 | B | 379,509 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 379,509 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2011 | 4690 | 8.2 | B | 373,516 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 373,516 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2012 | 4905 | 4.6 | B | 391,220 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (pure-play pharma, incl. royalties)Consolidated net sales (pure-play pharma, incl. royalties)consolidated net sales 391,220 Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 中外制药 | 2013 | 3648 | -25.6 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai ... 3,648" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 中外制药 | 2014 | 3576 | -2.0 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai ... 3,576" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 中外制药 | 2015 | 3297 | -7.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai ... 3,297" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 中外制药 | 2016 | 3699 | 12.2 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai ... 3,699" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 中外制药 | 2017 | 3688 | -0.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai ... 3,688" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 中外制药 | 2018 | 3649 | -1.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai ... 3,649" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 中外制药 | 2019 | 3996 | 9.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Chugai Pharmaceutical ... 3,996" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 中外制药 | 2020 | 3881 | -2.9 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 中外制药 | 2022 | 1120 | – | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 中外制药 | 2023 | 4036 | 260.4 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 丽珠集团 | 2000 | 143 | – | B | 1,182 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 118,205.67" (10,000 CNY) = 1,182.06 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2001 | 170 | 19.2 | B | 1,409 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 140,930.66" (10,000 CNY) = 1,409.31 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2002 | 195 | 14.7 | B | 1,616 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 161,642.92" (10,000 CNY) = 1,616.43 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2003 | 220 | 12.4 | B | 1,818 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 181,765.67" (10,000 CNY) = 1,817.66 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2004 | 189 | -14.2 | B | 1,560 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 156,030.81" (10,000 CNY) = 1,560.31 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2005 | 199 | 5.5 | B | 1,629 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 162,890.62" (10,000 CNY) = 1,628.91 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2006 | 190 | -4.4 | B | 1,515 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"主营业务收入 151,516.14" (10,000 CNY) = 1,515.16 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2007 | 230 | 21.0 | B | 1,748 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 174,810.84" (10,000 CNY) = 1,748.11 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2008 | 296 | 28.9 | B | 2,059 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 205,864.06" (10,000 CNY) = 2,058.64 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2009 | 380 | 28.2 | B | 2,596 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 259,584.71" (10,000 CNY) = 2,595.85 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2010 | 403 | 6.0 | B | 2,727 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 272,671.89" (10,000 CNY) = 2,726.72 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2011 | 489 | 21.5 | B | 3,163 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 316,291.53" (10,000 CNY) = 3,162.92 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2012 | 625 | 27.7 | B | 3,944 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 394,352.53" (10,000 CNY) = 3,943.53 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2013 | 751 | 20.2 | B | 4,619 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 461,868.00" (10,000 CNY) = 4,618.68 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2014 | 900 | 19.8 | B | 5,544 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 554,423.38" (10,000 CNY) = 5,544.23 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2015 | 1054 | 17.1 | B | 6,621 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 662,051.65" (10,000 CNY) = 6,620.52 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2016 | 1153 | 9.4 | B | 7,652 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 765,177.53" (10,000 CNY) = 7,651.78 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2017 | 1263 | 9.6 | B | 8,531 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入/营业收入 853,096.86" (10,000 CNY) = 8,530.97 m Sina Finance table for stock 000513. Pre-2007 line is main business revenue. |
| 丽珠集团 | 2018 | 1342 | 6.3 | B | 8,861 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 88.61亿元" = 8861 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2019 | 1359 | 1.3 | B | 9,385 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 93.85亿元" = 9385 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2020 | 1526 | 12.2 | B | 10,520 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 105.20亿元" = 10520 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2021 | 1871 | 22.6 | B | 12,064 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 120.64亿元" = 12064 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2022 | 1880 | 0.5 | B | 12,630 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 126.30亿元" = 12630 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2023 | 1757 | -6.6 | B | 12,430 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 124.30亿元" = 12430 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2024 | 1642 | -6.6 | B | 11,812 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 118.12亿元" = 11812 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 丽珠集团 | 2025 | 1672 | 1.9 | B | 12,020 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Livzon Pharmaceutical...Total revenue of the listed company Livzon Pharmaceutical Group (drugs plus APIs and diagnostics)"营业总收入 120.20亿元" = 12020 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2000 | 96 | – | B | 797 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 79,657.05" (10,000 CNY) = 796.57 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2001 | 109 | 13.2 | B | 901 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 90,144.02" (10,000 CNY) = 901.44 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2002 | 133 | 22.2 | B | 1,101 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 110,119.38" (10,000 CNY) = 1,101.19 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2003 | 163 | 22.3 | B | 1,346 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 134,634.63" (10,000 CNY) = 1,346.35 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2004 | 222 | 36.3 | B | 1,835 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 183,498.86" (10,000 CNY) = 1,834.99 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2005 | 299 | 34.9 | B | 2,451 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 245,083.98" (10,000 CNY) = 2,450.84 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2006 | 402 | 34.3 | B | 3,203 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"主营业务收入 320,273.74" (10,000 CNY) = 3,202.74 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2007 | 541 | 34.7 | B | 4,116 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 411,571.69" (10,000 CNY) = 4,115.72 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2008 | 824 | 52.2 | B | 5,723 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 572,319.87" (10,000 CNY) = 5,723.20 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2009 | 1050 | 27.4 | B | 7,172 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 717,178.40" (10,000 CNY) = 7,171.78 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2010 | 1489 | 41.8 | B | 10,075 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 1,007,543.78" (10,000 CNY) = 10,075.44 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2011 | 1751 | 17.6 | B | 11,312 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 1,131,232.24" (10,000 CNY) = 11,312.32 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2012 | 2170 | 23.9 | B | 13,687 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 1,368,682.45" (10,000 CNY) = 13,686.82 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2013 | 2573 | 18.6 | B | 15,815 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 1,581,479.09" (10,000 CNY) = 15,814.79 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2014 | 3054 | 18.7 | B | 18,814 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 1,881,436.64" (10,000 CNY) = 18,814.37 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2015 | 3301 | 8.1 | B | 20,738 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 2,073,812.62" (10,000 CNY) = 20,738.13 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2016 | 3376 | 2.3 | B | 22,411 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 2,241,065.44" (10,000 CNY) = 22,410.65 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2017 | 3600 | 6.7 | B | 24,315 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入/营业收入 2,431,461.40" (10,000 CNY) = 24,314.61 m Sina Finance table for stock 000538. Commerce (wholesale) is the larger part of the total from the 2000s; Pharm Exec 2019 (US$ 4,284 m = about RMB 29.6 bn) matches the group total, so the total is kept for consistency. Pre-2007 line is main business revenue. |
| 云南白药 | 2018 | 4092 | 13.7 | B | 27,017 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 270.17亿元" = 27017 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2019 | 4284 | 4.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Yunnan Baiyao Group ... 4,284" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 云南白药 | 2020 | 4749 | 10.8 | B | 32,743 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 327.43亿元" = 32743 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2021 | 5640 | 18.8 | B | 36,374 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 363.74亿元" = 36374 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2022 | 5432 | -3.7 | B | 36,488 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 364.88亿元" = 36488 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2023 | 5528 | 1.8 | B | 39,111 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 391.11亿元" = 39111 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2024 | 5564 | 0.6 | B | 40,033 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 400.33亿元" = 40033 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 云南白药 | 2025 | 5731 | 3.0 | B | 41,187 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue (own pharmaceutical/health products plus ph...Total revenue (own pharmaceutical/health products plus pharma commerce; same basis as the Pharm Exec 2019 row, which equals total revenue)"营业总收入 411.87亿元" = 41187 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 亚力兄制药 | 2014 | 2234 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Alexion ... 2,234" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 亚力兄制药 | 2015 | 2603 | 16.5 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Alexion ... 2,603" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 亚力兄制药 | 2016 | 3082 | 18.4 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Alexion ... 3,082" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 亚力兄制药 | 2017 | 3550 | 15.2 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Alexion ... 3,550" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 亚力兄制药 | 2018 | 4130 | 16.3 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Alexion ... 4,130" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 亚力兄制药 | 2019 | 4990 | 20.8 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Alexion Pharmaceuticals ... 4,990" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 亚力兄制药 | 2020 | 6069 | 21.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 亚力兄制药 | 2021 | 3804 | -37.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 优时比 | 2000 | 1662 | – | C | 1,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2001 | 1701 | 2.4 | C | 1,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2002 | 1607 | -5.5 | C | 1,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2003 | 2037 | 26.8 | C | 1,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2004 | 2363 | 16.0 | C | 1,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2005 | 2489 | 5.3 | C | 2,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2006 | 2889 | 16.0 | C | 2,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2007 | 4113 | 42.4 | C | 3,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2008 | 4852 | 18.0 | C | 3,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2009 | 4319 | -11.0 | C | 3,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2010 | 4116 | -4.7 | C | 3,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2011 | 4315 | 4.9 | C | 3,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2012 | 4116 | -4.6 | C | 3,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pharma pure-play, Schwarz Pharma from 2006)Total revenue (pharma pure-play, Schwarz Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 优时比 | 2013 | 3802 | -7.6 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 3,802" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 优时比 | 2014 | 3715 | -2.3 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 3,715" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 优时比 | 2015 | 3763 | 1.3 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 3,763" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 优时比 | 2016 | 4005 | 6.4 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 4,005" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 优时比 | 2017 | 4633 | 15.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 4,633" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 优时比 | 2018 | 5138 | 10.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 5,138" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 优时比 | 2019 | 5102 | -0.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"UCB ... 5,102" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 优时比 | 2020 | 5455 | 6.9 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 优时比 | 2021 | 6395 | 17.2 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 优时比 | 2022 | 5663 | -11.4 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 优时比 | 2023 | 5210 | -8.0 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 优时比 | 2024 | 6051 | 16.1 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 优时比 | 2025 | 8244 | 36.2 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 住友制药 | 2005 | 2000 | – | C | 226,120 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 245,783 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2006 | 2055 | 2.8 | C | 240,316 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 261,213 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2007 | 2133 | 3.8 | C | 242,873 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 263,992 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2008 | 2427 | 13.8 | C | 242,914 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 264,037 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2009 | 2939 | 21.1 | C | 272,560 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 296,261 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2010 | 4085 | 39.0 | C | 349,152 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 379,513 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2011 | 4085 | 0.0 | C | 322,363 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.92group net sales 350,395 x 0.92 Dainippon Sumitomo Pharma (merger Oct 2005, so FY Mar 2006 has Sumitomo Pharmaceuticals for half a year; Sepracor consolidated from Oct 2009); 8% assumed for food, chemicals, animal health. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 住友制药 | 2012 | 3286 | -19.6 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon ... 3,286" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 住友制药 | 2014 | 2944 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon ... 2,944" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 住友制药 | 2015 | 2902 | -1.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon ... 2,902" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 住友制药 | 2016 | 3197 | 10.2 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon ... 3,197" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 住友制药 | 2017 | 3528 | 10.4 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon ... 3,528" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 住友制药 | 2018 | 3543 | 0.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon ... 3,543" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 住友制药 | 2019 | 3623 | 2.3 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sumitomo Dainippon Pharma ... 3,623" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 住友制药 | 2020 | 4028 | 11.2 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 住友制药 | 2021 | 4602 | 14.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 健赞 | 2008 | 4220 | – | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)4100 / (1-2.9%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 健赞 | 2009 | 4100 | -2.8 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)genzyme 4.1 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 健赞 | 2010 | 4000 | -2.4 | C | phx_est | selected data / segment note | Total revenues x ~0.9 (Pharm Exec basis)Total revenues x ~0.9 (Pharm Exec basis)Genzyme revenue ~4.0-4.5 bn 2009-10; acquired by Sanofi Apr 2011 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵 | 2000 | 2863 | – | C | 3,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 先灵 | 2001 | 3134 | 9.5 | C | 3,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 先灵 | 2002 | 3876 | 23.7 | C | 4,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 先灵 | 2003 | 4980 | 28.5 | C | 4,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 先灵 | 2004 | 5971 | 19.9 | C | 4,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 先灵 | 2005 | 6597 | 10.5 | C | 5,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Schering AG total net sales (pharma pure-play, 2006 acqui...Schering AG total net sales (pharma pure-play, 2006 acquired by Bayer)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 先灵葆雅 | 2000 | 8500 | – | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2001 | 8600 | 1.2 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2002 | 9100 | 5.8 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2003 | 7300 | -19.8 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2004 | 7300 | 0.0 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2005 | 8500 | 16.4 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2006 | 9500 | 11.8 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2007 | 11000 | 15.8 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 先灵葆雅 | 2008 | 13500 | 22.7 | C | phx_est | selected data / segment note | Total net sales less consumer (and animal health from 2007)Total net sales less consumer (and animal health from 2007)Schering-Plough sales 9.8/9.8/10.2/8.3/8.3/9.5/10.6/12.7/18.5 bn (2000-08) less consumer ~1 and Intervet Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 兰伯西 | 2008 | 1678 | – | B | 72,414 INR m | phx_rbx_press+fx_fed_h10 | results notice | Consolidated net sales (pharma)Consolidated net sales (pharma)Net Sales Rs 724140.7 lacs for 2008 2008 and 2011 via search snippets only. 2009 restated in AR2010 (73,294 in the earlier release). December year-end. |
| 兰伯西 | 2009 | 1521 | -9.4 | A | 73,441 INR m | phx_rbx_ar2010+fx_fed_h10 | Directors report, consolidated sales | Consolidated net sales (pharma)Consolidated net sales (pharma)Rs. 85,507 millions against Rs.73,441 millions in the previous year December year-end. The AR2010 ten-year table gives the standalone company only (2001-2010), not used. |
| 兰伯西 | 2010 | 1874 | 23.2 | A | 85,507 INR m | phx_rbx_ar2010+fx_fed_h10 | Directors report, consolidated sales | Consolidated net sales (pharma)Consolidated net sales (pharma)consolidated sales of Rs. 85,507 millions December year-end. The AR2010 ten-year table gives the standalone company only (2001-2010), not used. |
| 兰伯西 | 2011 | 2147 | 14.6 | B | 99,769 INR m | phx_rbx_press+fx_fed_h10 | results notice | Consolidated net sales (pharma)Consolidated net sales (pharma)consolidated sales Rs 99,769 Mn 2008 and 2011 via search snippets only. 2009 restated in AR2010 (73,294 in the earlier release). December year-end. |
| 兰伯西 | 2012 | 2199 | 2.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ranbaxy ... 2,199" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 再生元 | 2015 | 2689 | – | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Regeneron ... 2,689" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 再生元 | 2016 | 3338 | 24.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Regeneron ... 3,338" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 再生元 | 2017 | 3718 | 11.4 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Regeneron ... 3,718" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 再生元 | 2018 | 4106 | 10.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Regeneron ... 4,106" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 再生元 | 2019 | 4834 | 17.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Regeneron ... 4,834" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 再生元 | 2020 | 5568 | 15.2 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 再生元 | 2021 | 12117 | 117.6 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 再生元 | 2022 | 6894 | -43.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 再生元 | 2023 | 7078 | 2.7 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 再生元 | 2024 | 7629 | 7.8 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 再生元 | 2025 | 6309 | -17.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 勃林格殷格翰 | 2000 | 3509 | – | C | 3,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2001 | 3851 | 9.7 | C | 4,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2002 | 5010 | 30.1 | C | 5,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2003 | 6564 | 31.0 | C | 5,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2004 | 8210 | 25.1 | C | 6,600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2005 | 9335 | 13.7 | C | 7,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2006 | 10425 | 11.7 | C | 8,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2007 | 12749 | 22.3 | C | 9,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2008 | 15146 | 18.8 | C | 10,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2009 | 14351 | -5.2 | C | 10,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2010 | 14205 | -1.0 | C | 10,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2011 | 15452 | 8.8 | C | 11,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2012 | 15050 | -2.6 | C | 11,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Boehringer Ingelheim prescription medicines net salesBoehringer Ingelheim prescription medicines net salesRecalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 勃林格殷格翰 | 2013 | 14468 | -3.9 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer Ingelheim ... 14,468" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 勃林格殷格翰 | 2014 | 13903 | -3.9 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer Ingelheim ... 13,903" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 勃林格殷格翰 | 2015 | 12348 | -11.2 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer Ingelheim ... 12,348" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 勃林格殷格翰 | 2016 | 13316 | 7.8 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer Ingelheim ... 13,316" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 勃林格殷格翰 | 2017 | 14262 | 7.1 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer Ingelheim ... 14,262" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 勃林格殷格翰 | 2018 | 14834 | 4.0 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer Ingelheim ... 14,834" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 勃林格殷格翰 | 2019 | 15629 | 5.4 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Boehringer-Ingelheim ... 15,629" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 勃林格殷格翰 | 2020 | 16456 | 5.3 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 勃林格殷格翰 | 2021 | 17806 | 8.2 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 勃林格殷格翰 | 2022 | 19473 | 9.4 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 勃林格殷格翰 | 2023 | 20613 | 5.9 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 勃林格殷格翰 | 2024 | 22175 | 7.6 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 勃林格殷格翰 | 2025 | 23817 | 7.4 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 华东医药 | 2000 | 39 | – | C | 324 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2000-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 162,043.08" (10,000 CNY) = 1,620.43 m x 20% = 324.09 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2001 | 46 | 16.5 | C | 377 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2001-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 188,722.05" (10,000 CNY) = 1,887.22 m x 20% = 377.44 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2002 | 50 | 10.6 | C | 418 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2002-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 208,775.74" (10,000 CNY) = 2,087.76 m x 20% = 417.55 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2003 | 57 | 12.5 | C | 470 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2003-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 234,867.82" (10,000 CNY) = 2,348.68 m x 20% = 469.74 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2004 | 70 | 23.6 | C | 581 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2004-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 290,354.18" (10,000 CNY) = 2,903.54 m x 20% = 580.71 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2005 | 86 | 22.0 | C | 701 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2005-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 350,594.62" (10,000 CNY) = 3,505.95 m x 20% = 701.19 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2006 | 99 | 16.2 | C | 793 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2006-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 396,316.38" (10,000 CNY) = 3,963.16 m x 20% = 792.63 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2007 | 128 | 28.4 | C | 971 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2007-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 485,341.34" (10,000 CNY) = 4,853.41 m x 20% = 970.68 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2008 | 173 | 35.7 | C | 1,203 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2008-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 601,648.61" (10,000 CNY) = 6,016.49 m x 20% = 1,203.30 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2009 | 229 | 32.2 | C | 1,565 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2009-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 782,487.22" (10,000 CNY) = 7,824.87 m x 20% = 1,564.97 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2010 | 265 | 15.7 | C | 1,794 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2010-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 897,183.65" (10,000 CNY) = 8,971.84 m x 20% = 1,794.37 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2011 | 345 | 29.9 | C | 2,226 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2011-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 1,113,137.24" (10,000 CNY) = 11,131.37 m x 20% = 2,226.27 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2012 | 462 | 34.2 | C | 2,916 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2012-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 1,457,923.04" (10,000 CNY) = 14,579.23 m x 20% = 2,915.85 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2013 | 544 | 17.7 | C | 3,344 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2013-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 1,671,798.64" (10,000 CNY) = 16,717.99 m x 20% = 3,343.60 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2014 | 615 | 13.1 | C | 3,789 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2014-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 1,894,737.91" (10,000 CNY) = 18,947.38 m x 20% = 3,789.48 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2015 | 692 | 12.4 | C | 4,345 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2015-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 2,172,738.35" (10,000 CNY) = 21,727.38 m x 20% = 4,345.48 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2016 | 765 | 10.5 | C | 5,076 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2016-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 2,537,966.75" (10,000 CNY) = 25,379.67 m x 20% = 5,075.93 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2017 | 824 | 7.8 | C | 5,566 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2017-12-31 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue"营业收入 2,783,182.31" (10,000 CNY) = 27,831.82 m x 20% = 5,566.36 m Huadong Medicine's total is mostly its commercial (wholesale) arm; own manufacturing is roughly a fifth to a quarter in the 2010s (recollection of annual-report segment splits, not read from the document). The 20% is a flat assumption; likely lower before 2008 and a little higher after 2015. |
| 华东医药 | 2018 | 929 | 12.7 | C | 6,133 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue306.63亿 total x 20% = 6132.6 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2019 | 1027 | 10.5 | C | 7,089 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue354.46亿 total x 20% = 7089.2 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2020 | 977 | -4.8 | C | 6,737 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue336.83亿 total x 20% = 6736.6 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2021 | 1072 | 9.7 | C | 6,913 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue345.63亿 total x 20% = 6912.6 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2022 | 1123 | 4.8 | C | 7,543 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue377.15亿 total x 20% = 7543.0 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2023 | 1148 | 2.3 | C | 8,125 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue406.24亿 total x 20% = 8124.8 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2024 | 1165 | 1.4 | C | 8,381 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue419.06亿 total x 20% = 8381.2 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华东医药 | 2025 | 1214 | 4.2 | C | 8,722 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing estimated as 20% of total re...Pharmaceutical manufacturing estimated as 20% of total revenue436.12亿 total x 20% = 8722.4 RMB m Same estimate as 2012-2017: 20% of consolidated revenue; share not verified for later years (grade C) |
| 华北制药 | 2000 | 286 | – | B | 2,369 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 236,882.01" (10,000 CNY) = 2,368.82 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2001 | 348 | 21.7 | B | 2,882 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 288,171.11" (10,000 CNY) = 2,881.71 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2002 | 372 | 6.7 | B | 3,076 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 307,610.49" (10,000 CNY) = 3,076.10 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2003 | 435 | 17.1 | B | 3,604 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 360,366.12" (10,000 CNY) = 3,603.66 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2004 | 502 | 15.3 | B | 4,155 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 415,542.72" (10,000 CNY) = 4,155.43 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2005 | 487 | -3.1 | B | 3,987 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 398,713.91" (10,000 CNY) = 3,987.14 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2006 | 455 | -6.6 | B | 3,624 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"主营业务收入 362,401.93" (10,000 CNY) = 3,624.02 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2007 | 558 | 22.7 | B | 4,241 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 424,058.71" (10,000 CNY) = 4,240.59 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2008 | 707 | 26.8 | B | 4,911 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 491,095.71" (10,000 CNY) = 4,910.96 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2009 | 715 | 1.1 | B | 4,883 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 488,252.21" (10,000 CNY) = 4,882.52 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2010 | 1520 | 112.6 | B | 10,287 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 1,028,664.34" (10,000 CNY) = 10,286.64 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2011 | 1878 | 23.6 | B | 12,137 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 1,213,674.57" (10,000 CNY) = 12,136.75 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2012 | 1764 | -6.1 | B | 11,126 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 1,112,570.62" (10,000 CNY) = 11,125.71 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2013 | 2023 | 14.7 | B | 12,438 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 1,243,814.37" (10,000 CNY) = 12,438.14 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2014 | 1526 | -24.6 | B | 9,401 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 940,097.27" (10,000 CNY) = 9,400.97 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2015 | 1258 | -17.6 | B | 7,902 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 790,250.23" (10,000 CNY) = 7,902.50 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2016 | 1217 | -3.2 | B | 8,082 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 808,246.28" (10,000 CNY) = 8,082.46 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2017 | 1141 | -6.2 | B | 7,709 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入/营业收入 770,912.19" (10,000 CNY) = 7,709.12 m Sina Finance table for stock 600812. 2010 jump = consolidation of group parent assets. Pre-2007 line is main business revenue. |
| 华北制药 | 2018 | 1396 | 22.3 | B | 9,214 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 92.14亿元" = 9214 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2019 | 1659 | 18.9 | B | 11,457 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 114.57亿元" = 11457 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2020 | 1667 | 0.4 | B | 11,493 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 114.93亿元" = 11493 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2021 | 1610 | -3.4 | B | 10,385 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 103.85亿元" = 10385 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2022 | 1563 | -2.9 | B | 10,500 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 105.00亿元" = 10500 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2023 | 1430 | -8.5 | B | 10,120 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 101.20亿元" = 10120 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2024 | 1372 | -4.1 | B | 9,870 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 98.70亿元" = 9870 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华北制药 | 2025 | 1286 | -6.3 | B | 9,242 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (antibiotics, vitamin...Total revenue of the listed company (antibiotics, vitamins, formulations)"营业总收入 92.42亿元" = 9242 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2000 | 198 | – | B | 1,635 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 163,500.67" (10,000 CNY) = 1,635.01 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2001 | 226 | 14.5 | B | 1,871 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 187,120.28" (10,000 CNY) = 1,871.20 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2002 | 263 | 16.1 | B | 2,173 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 217,318.87" (10,000 CNY) = 2,173.19 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2003 | 324 | 23.6 | B | 2,686 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 268,592.01" (10,000 CNY) = 2,685.92 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2004 | 300 | -7.6 | B | 2,482 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 248,160.36" (10,000 CNY) = 2,481.60 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2005 | 366 | 22.0 | B | 2,997 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 299,669.16" (10,000 CNY) = 2,996.69 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2006 | 364 | -0.4 | B | 2,904 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"主营业务收入 290,423.25" (10,000 CNY) = 2,904.23 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2007 | 457 | 25.5 | B | 3,478 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 347,756.12" (10,000 CNY) = 3,477.56 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2008 | 621 | 35.9 | B | 4,316 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 431,618.69" (10,000 CNY) = 4,316.19 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2009 | 710 | 14.3 | B | 4,853 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 485,271.70" (10,000 CNY) = 4,852.72 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2010 | 645 | -9.2 | B | 4,365 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 436,515.33" (10,000 CNY) = 4,365.15 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2011 | 855 | 32.6 | B | 5,525 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 552,522.29" (10,000 CNY) = 5,525.22 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2012 | 1092 | 27.8 | B | 6,891 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 689,110.26" (10,000 CNY) = 6,891.10 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2013 | 1269 | 16.2 | B | 7,802 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 780,160.37" (10,000 CNY) = 7,801.60 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2014 | 1181 | -6.9 | B | 7,277 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 727,658.56" (10,000 CNY) = 7,276.59 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2015 | 1258 | 6.5 | B | 7,900 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 790,018.96" (10,000 CNY) = 7,900.19 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2016 | 1353 | 7.6 | B | 8,982 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 898,172.11" (10,000 CNY) = 8,981.72 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2017 | 1646 | 21.7 | B | 11,120 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入/营业收入 1,111,991.64" (10,000 CNY) = 11,119.92 m Sina Finance table for stock 000999. Before 2008 the owner was Sanjiu Group; same listed company, series continuous. |
| 华润三九 | 2018 | 2034 | 23.5 | B | 13,428 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 134.28亿元" = 13428 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2019 | 2143 | 5.4 | B | 14,794 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 147.94亿元" = 14794 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2020 | 1978 | -7.7 | B | 13,637 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 136.37亿元" = 13637 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2021 | 2410 | 21.9 | B | 15,544 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 155.44亿元" = 15544 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2022 | 2691 | 11.7 | B | 18,079 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 180.79亿元" = 18079 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2023 | 3497 | 29.9 | B | 24,739 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 247.39亿元" = 24739 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2024 | 3838 | 9.8 | B | 27,617 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 276.17亿元" = 27617 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润三九 | 2025 | 4397 | 14.6 | B | 31,603 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Sanji...Total revenue of the listed company China Resources Sanjiu (999 brand; CR owner from 2008)"营业总收入 316.03亿元" = 31603 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2000 | 142 | – | B | 1,175 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 117,533.59" (10,000 CNY) = 1,175.34 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2001 | 289 | 103.7 | B | 2,394 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 239,376.91" (10,000 CNY) = 2,393.77 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2002 | 448 | 55.0 | B | 3,710 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 371,008.74" (10,000 CNY) = 3,710.09 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2003 | 517 | 15.4 | B | 4,280 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 428,000.98" (10,000 CNY) = 4,280.01 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2004 | 509 | -1.6 | B | 4,210 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 420,974.07" (10,000 CNY) = 4,209.74 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2005 | 563 | 10.6 | B | 4,611 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 461,061.95" (10,000 CNY) = 4,610.62 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2006 | 510 | -9.3 | B | 4,067 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"主营业务收入 406,673.72" (10,000 CNY) = 4,066.74 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2007 | 599 | 17.5 | B | 4,557 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 455,661.64" (10,000 CNY) = 4,556.62 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2008 | 713 | 19.0 | B | 4,952 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 495,152.44" (10,000 CNY) = 4,951.52 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2009 | 738 | 3.5 | B | 5,038 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 503,794.64" (10,000 CNY) = 5,037.95 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2010 | 793 | 7.5 | B | 5,367 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 536,679.58" (10,000 CNY) = 5,366.80 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2011 | 988 | 24.6 | B | 6,383 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 638,337.53" (10,000 CNY) = 6,383.38 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2012 | 1108 | 12.2 | B | 6,989 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 698,932.34" (10,000 CNY) = 6,989.32 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2013 | 1112 | 0.3 | B | 6,835 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 683,457.43" (10,000 CNY) = 6,834.57 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2014 | 695 | -37.5 | B | 4,281 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 428,096.10" (10,000 CNY) = 4,280.96 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2015 | 818 | 17.7 | B | 5,138 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 513,839.54" (10,000 CNY) = 5,138.40 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2016 | 828 | 1.2 | B | 5,495 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 549,480.39" (10,000 CNY) = 5,494.80 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2017 | 951 | 14.9 | B | 6,422 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入/营业收入 642,184.68" (10,000 CNY) = 6,421.85 m Sina Finance table for stock 600062. The 2014 dip reflects a disposal/reclassification of commerce as reported. |
| 华润双鹤 | 2018 | 1246 | 31.0 | B | 8,225 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 82.25亿元" = 8225 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2019 | 1359 | 9.1 | B | 9,381 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 93.81亿元" = 9381 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2020 | 1233 | -9.2 | B | 8,504 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 85.04亿元" = 8504 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2021 | 1413 | 14.5 | B | 9,112 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 91.12亿元" = 9112 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2022 | 1433 | 1.4 | B | 9,625 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 96.25亿元" = 9625 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2023 | 1599 | 11.6 | B | 11,310 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 113.10亿元" = 11310 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2024 | 1558 | -2.5 | B | 11,212 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 112.12亿元" = 11212 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 华润双鹤 | 2025 | 1531 | -1.8 | B | 11,001 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company China Resources Doubl...Total revenue of the listed company China Resources Double-Crane (Beijing Double-Crane; CR from 2008)"营业总收入 110.01亿元" = 11001 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 协和麒麟 | 2010 | 3165 | – | C | 277,204 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67group net sales 413,738 x 0.67 Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 协和麒麟 | 2011 | 2892 | -8.6 | C | 230,294 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67group net sales 343,722 x 0.67 Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 协和麒麟 | 2012 | 2798 | -3.2 | C | 223,216 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Pharmaceutical revenue estimate = group net sales x 0.67Pharmaceutical revenue estimate = group net sales x 0.67group net sales 333,158 x 0.67 Share 0.67 calibrated to the Pharm Exec 2014 row for 2013 (2,334 US$ m x 97.6 = 228 bn / 341 bn); the group includes Kyowa Hakko Bio and chemicals. Kyowa Hakko Kirin formed Oct 2008; the 9-month transition period 2009 is left out. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 协和麒麟 | 2013 | 2334 | -16.6 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Kyowa Hakko Kirin ... 2,334" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 协和麒麟 | 2014 | 2157 | -7.6 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Kyowa Hakko Kirin ... 2,157" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 协和麒麟 | 2016 | 2228 | – | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Kyowa Hakko Kirin ... 2,228" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 协和麒麟 | 2017 | 2272 | 2.0 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Kyowa Hakko Kirin ... 2,272" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 协和麒麟 | 2021 | 2959 | – | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 博士康 | 2013 | 4196 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Valeant ... 4,196" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 博士康 | 2014 | 5007 | 19.3 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Valeant ... 5,007" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 博士康 | 2015 | 7013 | 40.1 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Valeant ... 7,013" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 博士康 | 2016 | 6183 | -11.8 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Valeant ... 6,183" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 博士康 | 2017 | 5053 | -18.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Valeant ... 5,053" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 博士康 | 2018 | 4631 | -8.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bausch Health ... 4,631" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 博士康 | 2019 | 5295 | 14.3 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bausch Health Companies ... 5,295" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 博士康 | 2020 | 4884 | -7.8 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 博士康 | 2021 | 4924 | 0.8 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 博士康 | 2022 | 6569 | 33.4 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 博士康 | 2023 | 4418 | -32.7 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 博士康 | 2024 | 4977 | 12.7 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 博士康 | 2025 | 5406 | 8.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 卫材 | 2000 | 2719 | – | C | 300,211 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 361,700 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2001 | 2868 | 5.5 | C | 358,289 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 431,673 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2002 | 3180 | 10.9 | C | 387,278 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 466,600 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2003 | 3682 | 15.8 | C | 415,083 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 500,100 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2004 | 4118 | 11.9 | C | 442,390 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 533,000 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2005 | 4414 | 7.2 | C | 499,039 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 601,252 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2006 | 4785 | 8.4 | C | 559,512 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 674,111 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2007 | 5353 | 11.9 | C | 609,457 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 734,286 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2008 | 6484 | 21.1 | C | 648,847 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 781,743 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2009 | 7187 | 10.8 | C | 666,616 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 803,152 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2010 | 7467 | 3.9 | C | 638,199 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 768,914 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2011 | 6816 | -8.7 | C | 537,820 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.83group net sales 647,976 x 0.83 Share 0.83 calibrated to the Pharm Exec 2014 row for FY2012/13 (4,821 US$ m x 97.6 = 470 bn / 574 bn = 0.82); Eisai also had food chemicals, diagnostics, contract manufacturing. Source page text gives FY2010/11 as 7,689.1 oku yen vs 768,914 in its table; the table is used. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 卫材 | 2012 | 4821 | -29.3 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 4,821" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 卫材 | 2014 | 4422 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 4,422" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 卫材 | 2015 | 3909 | -11.6 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 3,909" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 卫材 | 2016 | 4301 | 10.0 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 4,301" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 卫材 | 2017 | 4359 | 1.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 4,359" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 卫材 | 2018 | 4531 | 3.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 4,531" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 卫材 | 2019 | 4703 | 3.8 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eisai ... 4,703" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 卫材 | 2020 | 5107 | 8.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 卫材 | 2021 | 5224 | 2.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 卫材 | 2022 | 4596 | -12.0 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 卫材 | 2023 | 4305 | -6.3 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 卫材 | 2024 | 4536 | 5.4 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 卫材 | 2025 | 4775 | 5.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 史达德 | 2000 | 554 | – | C | 600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2001 | 627 | 13.1 | C | 700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2002 | 756 | 20.6 | C | 800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2003 | 1019 | 34.7 | C | 900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2004 | 1244 | 22.1 | C | 1,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2005 | 1369 | 10.1 | C | 1,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2006 | 1633 | 19.3 | C | 1,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2007 | 1919 | 17.5 | C | 1,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2008 | 2206 | 14.9 | C | 1,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2009 | 2369 | 7.4 | C | 1,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2010 | 2522 | 6.5 | C | 1,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2011 | 2645 | 4.9 | C | 1,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2012 | 2701 | 2.1 | C | 2,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | STADA Arzneimittel group sales (generics)STADA Arzneimittel group sales (generics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 史达德 | 2013 | 2407 | -10.9 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"STADA ... 2,407" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 史达德 | 2014 | 2405 | -0.1 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"STADA ... 2,405" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 史达德 | 2017 | 2348 | – | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"STADA ... 2,348" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 史达德 | 2018 | 2467 | 5.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"STADA ... 2,467" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 史达德 | 2020 | 2823 | – | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 史达德 | 2021 | 3097 | 9.7 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 史达德 | 2023 | 3896 | – | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 史达德 | 2024 | 3930 | 0.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 史达德 | 2025 | 4017 | 2.2 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 吉利德科学 | 2002 | 466 | – | C | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2004 | 1325 | – | B | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2005 | 2028 | 53.1 | B | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2006 | 3026 | 49.2 | B | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2007 | 4230 | 39.8 | B | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2008 | 5130 | 21.3 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)6500 / (1+26.8%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 吉利德科学 | 2009 | 6500 | 26.7 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)gilead 6.5 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 吉利德科学 | 2010 | 7949 | 22.3 | B | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2011 | 8100 | 1.9 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)gilead $8.1 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 吉利德科学 | 2012 | 9702 | 19.8 | B | phx_est | selected data / segment note | Total revenuesTotal revenuesGilead total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 吉利德科学 | 2013 | 10804 | 11.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Sciences ... 10,804" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 吉利德科学 | 2014 | 24474 | 126.5 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Sciences ... 24,474" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 吉利德科学 | 2015 | 32151 | 31.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Sciences ... 32,151" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 吉利德科学 | 2016 | 29992 | -6.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Sciences ... 29,992" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 吉利德科学 | 2017 | 25662 | -14.4 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Sciences ... 25,662" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 吉利德科学 | 2018 | 21677 | -15.5 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Sciences ... 21,677" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 吉利德科学 | 2019 | 21703 | 0.1 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Gilead Science ... 21,703" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 吉利德科学 | 2020 | 23806 | 9.7 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 吉利德科学 | 2021 | 27005 | 13.4 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 吉利德科学 | 2022 | 26615 | -1.4 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 吉利德科学 | 2023 | 26461 | -0.6 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 吉利德科学 | 2024 | 28028 | 5.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 吉利德科学 | 2025 | 28828 | 2.9 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 同仁堂 | 2000 | 124 | – | B | 1,025 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 102,513.17" (10,000 CNY) = 1,025.13 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2001 | 195 | 57.3 | B | 1,612 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 161,250.39" (10,000 CNY) = 1,612.50 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2002 | 241 | 23.6 | B | 1,993 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 199,296.29" (10,000 CNY) = 1,992.96 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2003 | 263 | 9.1 | B | 2,174 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 217,364.96" (10,000 CNY) = 2,173.65 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2004 | 297 | 13.0 | B | 2,457 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 245,674.09" (10,000 CNY) = 2,456.74 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2005 | 319 | 7.5 | B | 2,614 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 261,355.38" (10,000 CNY) = 2,613.55 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2006 | 302 | -5.3 | B | 2,408 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"主营业务收入 240,781.26" (10,000 CNY) = 2,407.81 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2007 | 355 | 17.7 | B | 2,703 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 270,285.09" (10,000 CNY) = 2,702.85 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2008 | 423 | 19.0 | B | 2,939 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 293,904.95" (10,000 CNY) = 2,939.05 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2009 | 476 | 12.4 | B | 3,250 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 325,021.99" (10,000 CNY) = 3,250.22 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2010 | 565 | 18.8 | B | 3,824 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 382,444.61" (10,000 CNY) = 3,824.45 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2011 | 945 | 67.3 | B | 6,108 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 610,838.37" (10,000 CNY) = 6,108.38 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2012 | 1190 | 25.8 | B | 7,504 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 750,403.20" (10,000 CNY) = 7,504.03 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2013 | 1418 | 19.2 | B | 8,715 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 871,464.74" (10,000 CNY) = 8,714.65 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2014 | 1572 | 10.9 | B | 9,686 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 968,586.75" (10,000 CNY) = 9,685.87 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2015 | 1721 | 9.4 | B | 10,809 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 1,080,876.12" (10,000 CNY) = 10,808.76 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2016 | 1821 | 5.8 | B | 12,091 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 1,209,074.01" (10,000 CNY) = 12,090.74 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2017 | 1980 | 8.7 | B | 13,376 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入/营业收入 1,337,596.63" (10,000 CNY) = 13,375.97 m Sina Finance table for stock 600085 (Beijing Tong Ren Tang Co Ltd, not the HK-listed Tong Ren Tang Technologies). 2011 step = injection of group Tong Ren Tang pharmaceutical assets. |
| 同仁堂 | 2018 | 2152 | 8.7 | B | 14,209 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 142.09亿元" = 14209 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2019 | 1923 | -10.6 | B | 13,277 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 132.77亿元" = 13277 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2020 | 1860 | -3.3 | B | 12,826 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 128.26亿元" = 12826 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2021 | 2264 | 21.7 | B | 14,603 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 146.03亿元" = 14603 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2022 | 2288 | 1.1 | B | 15,372 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 153.72亿元" = 15372 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2023 | 2525 | 10.3 | B | 17,861 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 178.61亿元" = 17861 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2024 | 2585 | 2.4 | B | 18,597 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 185.97亿元" = 18597 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 同仁堂 | 2025 | 2401 | -7.1 | B | 17,256 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Beijing Tong Ren Tang...Total revenue of the listed company Beijing Tong Ren Tang Co (TCM manufacturing plus retail)"营业总收入 172.56亿元" = 17256 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2000 | 780 | – | B | 6,455 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 645,531.53" (10,000 CNY) = 6,455.32 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2001 | 649 | -16.8 | B | 5,370 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 537,001.85" (10,000 CNY) = 5,370.02 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2002 | 787 | 21.4 | B | 6,518 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 651,750.26" (10,000 CNY) = 6,517.50 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2003 | 838 | 6.4 | B | 6,936 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 693,616.66" (10,000 CNY) = 6,936.17 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2004 | 869 | 3.7 | B | 7,191 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 719,118.43" (10,000 CNY) = 7,191.18 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2005 | 1039 | 19.6 | B | 8,510 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 851,036.24" (10,000 CNY) = 8,510.36 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2006 | 1158 | 11.4 | B | 9,228 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"主营业务收入 922,817.96" (10,000 CNY) = 9,228.18 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2007 | 1090 | -5.8 | B | 8,290 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 829,026.99" (10,000 CNY) = 8,290.27 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2008 | 1396 | 28.0 | B | 9,695 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 969,506.81" (10,000 CNY) = 9,695.07 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2009 | 1563 | 12.0 | B | 10,677 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,067,730.06" (10,000 CNY) = 10,677.30 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2010 | 1852 | 18.5 | B | 12,535 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,253,543.98" (10,000 CNY) = 12,535.44 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2011 | 2087 | 12.7 | B | 13,487 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,348,696.04" (10,000 CNY) = 13,486.96 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2012 | 2800 | 34.2 | B | 17,663 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,766,294.69" (10,000 CNY) = 17,662.95 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2013 | 2943 | 5.1 | B | 18,092 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,809,193.45" (10,000 CNY) = 18,091.93 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2014 | 2680 | -8.9 | B | 16,509 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,650,891.25" (10,000 CNY) = 16,508.91 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2015 | 2524 | -5.8 | B | 15,856 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,585,620.78" (10,000 CNY) = 15,856.21 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2016 | 2128 | -15.7 | B | 14,127 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,412,688.60" (10,000 CNY) = 14,126.89 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2017 | 1779 | -16.4 | B | 12,018 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入/营业收入 1,201,753.13" (10,000 CNY) = 12,017.53 m Sina Finance table for stock 600664. Includes the trading arm; falls after 2013 with the sales slump. |
| 哈药集团 | 2018 | 1638 | -7.9 | B | 10,814 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 108.14亿元" = 10814 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2019 | 1713 | 4.6 | B | 11,825 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 118.25亿元" = 11825 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2020 | 1565 | -8.7 | B | 10,788 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 107.88亿元" = 10788 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2021 | 1985 | 26.9 | B | 12,802 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 128.02亿元" = 12802 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2022 | 2056 | 3.6 | B | 13,809 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 138.09亿元" = 13809 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2023 | 2185 | 6.3 | B | 15,457 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 154.57亿元" = 15457 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2024 | 2248 | 2.9 | B | 16,176 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 161.76亿元" = 16176 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 哈药集团 | 2025 | 2221 | -1.2 | B | 15,964 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Harbin Pharmaceutical...Total revenue of the listed company Harbin Pharmaceutical Group Co (drugs plus pharma distribution)"营业总收入 159.64亿元" = 15964 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 因塞特 | 2022 | 3747 | – | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 因塞特 | 2023 | 3165 | -15.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 因塞特 | 2024 | 3619 | 14.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 因塞特 | 2025 | 4354 | 20.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 基因泰克 | 2004 | 4621 | – | B | phx_est | selected data / segment note | Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)Genentech total operating revenues; acquired by Roche Mar 2009 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 基因泰克 | 2005 | 6633 | 43.5 | B | phx_est | selected data / segment note | Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)Genentech total operating revenues; acquired by Roche Mar 2009 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 基因泰克 | 2006 | 9284 | 40.0 | B | phx_est | selected data / segment note | Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)Genentech total operating revenues; acquired by Roche Mar 2009 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 基因泰克 | 2007 | 11724 | 26.3 | B | phx_est | selected data / segment note | Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)Genentech total operating revenues; acquired by Roche Mar 2009 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 基因泰克 | 2008 | 13418 | 14.4 | B | phx_est | selected data / segment note | Total operating revenues (product sales + royalties + con...Total operating revenues (product sales + royalties + contract)Genentech total operating revenues; acquired by Roche Mar 2009 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 基立福 | 2000 | 185 | – | C | 200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2001 | 224 | 21.2 | C | 250 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 250 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2002 | 378 | 68.9 | C | 400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2003 | 566 | 49.6 | C | 500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2004 | 746 | 31.9 | C | 600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2005 | 871 | 16.7 | C | 700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2006 | 1005 | 15.3 | C | 800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2007 | 1234 | 22.8 | C | 900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2008 | 1470 | 19.2 | C | 1,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2009 | 1533 | 4.2 | C | 1,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2010 | 1726 | 12.6 | C | 1,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2011 | 3898 | 125.8 | C | 2,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2012 | 3988 | 2.3 | C | 3,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net revenues (plasma-derived pharma, Diagnostic/Hos...Total net revenues (plasma-derived pharma, Diagnostic/Hospital incl.)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 基立福 | 2013 | 3245 | -18.6 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 3,245" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 基立福 | 2014 | 3255 | 0.3 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 3,255" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 基立福 | 2015 | 3365 | 3.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 3,365" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 基立福 | 2016 | 3572 | 6.2 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 3,572" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 基立福 | 2017 | 3876 | 8.5 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 3,876" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 基立福 | 2018 | 4154 | 7.2 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 4,154" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 基立福 | 2019 | 4471 | 7.6 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Grifols ... 4,471" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 基立福 | 2021 | 4516 | – | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 基立福 | 2022 | 4864 | 7.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 基立福 | 2023 | 6012 | 23.6 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 基立福 | 2024 | 6646 | 10.5 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 基立福 | 2025 | 7332 | 10.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 复星医药 | 2000 | 42 | – | C | 346 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2000-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 576.14 m x 60% = 345.68 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2001 | 53 | 27.0 | C | 439 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2001-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 731.59 m x 60% = 438.95 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2002 | 76 | 42.6 | C | 626 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2002-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 1,043.19 m x 60% = 625.92 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2003 | 158 | 108.9 | C | 1,307 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2003-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 2,178.79 m x 60% = 1,307.27 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2004 | 179 | 13.1 | C | 1,478 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2004-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 2,463.52 m x 60% = 1,478.11 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2005 | 223 | 25.1 | C | 1,830 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2005-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 3,050.15 m x 60% = 1,830.09 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2006 | 239 | 6.8 | C | 1,901 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2006-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 3,168.68 m x 60% = 1,901.21 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2007 | 291 | 22.2 | C | 2,216 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2007-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 3,693.30 m x 60% = 2,215.98 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2008 | 326 | 11.8 | C | 2,264 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2008-12-31 | Pharmaceutical manufacturing estimated as 60% of total re...Pharmaceutical manufacturing estimated as 60% of total revenuetotal 3,773.23 m x 60% = 2,263.94 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2009 | 333 | 2.2 | B | 2,275 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue2,812 / 1.2361 (2010 segment 2,812, +23.61%) Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2010 | 415 | 24.7 | B | 2,812 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue2010 pharmaceutical manufacturing segment revenue RMB 2.812 bn, +23.61% Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2011 | 622 | 49.8 | C | 4,021 CNY m | phx_cn_sina+phx_cn_est+fx_fed_h10 | Sina Finance income statement 2011-12-31 | Pharmaceutical manufacturing estimated as 62% of total re...Pharmaceutical manufacturing estimated as 62% of total revenuetotal 6,485.54 m x 62% = 4,021.04 m Share taken from 2009-2012 segment results (about 59%, 62%, 63% of total); Fosun also ran distribution, retail and devices. Pre-2009 share is a flat assumption. |
| 复星医药 | 2012 | 734 | 18.0 | B | 4,633 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue6,524 / 1.4082 (2013 segment 6,524, +40.82% on 2012) Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2013 | 1061 | 44.5 | B | 6,524 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue RMB 6,524 m, +40.82% Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2014 | 1191 | 12.2 | B | 7,338 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenueR&D RMB 452 m = 6.16% of segment revenue -> 452/0.0616 = 7,338 Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2015 | 1408 | 18.2 | B | 8,843 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenueSegment revenue 8,843 (comparative in 2017 annual results) Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2016 | 1529 | 8.6 | B | 10,150 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenueSegment revenue 10,150, +14.78% Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2017 | 1931 | 26.3 | B | 13,043 CNY m | phx_cn_fosun+fx_fed_h10 | Segment information (read via search summaries of Fosun results and releases, documents not opened) | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenueSegment revenue 13,043 (2017 annual results; a Fosun release gives 13,195.47) Segment as reported by Fosun Pharma; distribution/retail (Guoda) and medical-device segments excluded. 2017 group revenue 18.5 bn. |
| 复星医药 | 2018 | 2785 | 44.2 | C | 18,390 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)group 249.18亿 x 73.80% = 18389 RMB m Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved |
| 复星医药 | 2019 | 3157 | 13.3 | B | 21,796 CNY m | phx_cn_10jqka+phx_cn_fosun_rep+fx_fed... | annual table, row 营业总收入 | Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)group 285.85亿 x 76.25% = 21796 RMB m Broker note quotes pharma share 76.25% in 2019 (71.33% in 2017); segment table not retrieved |
| 复星医药 | 2020 | 3341 | 5.8 | C | 23,033 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)group 303.07亿 x 76.00% = 23033 RMB m Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved |
| 复星医药 | 2021 | 4113 | 23.1 | C | 26,528 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)group 390.11亿 x 68.00% = 26527 RMB m Share interpolated between the reported 2017/2019 and 2022/2023 shares (about 68-76%); segment table not retrieved |
| 复星医药 | 2022 | 4587 | 11.5 | B | 30,810 CNY m | phx_cn_fosun_rep+fx_fed_h10 | article text | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue2023 pharma 302.22亿, -1.91% yoy => 2022 = 302.22/0.9809 = 30,811 Backed out from the reported 2023 figure and its growth rate |
| 复星医药 | 2023 | 4272 | -6.9 | B | 30,222 CNY m | phx_cn_fosun_rep+fx_fed_h10 | article text | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenue"制药板块 302.22亿元, -1.91%" Article reprint of the annual report |
| 复星医药 | 2024 | 4109 | -3.8 | C | 29,568 CNY m | phx_cn_10jqka+phx_cn_est+fx_fed_h10 | annual table, row 营业总收入 | Pharmaceutical manufacturing and R&D segment revenue (est...Pharmaceutical manufacturing and R&D segment revenue (estimated as share of group revenue)group 410.67亿 x 72% = 29,568 RMB m Share of about 72% bracketed by 73.0% (2023) and 71.6% (2025); segment table not retrieved |
| 复星医药 | 2025 | 4151 | 1.0 | B | 29,834 CNY m | phx_cn_fosun_ann25+fx_fed_h10 | results summary | Pharmaceutical manufacturing and R&D segment revenuePharmaceutical manufacturing and R&D segment revenueinnovative drug revenue RMB 9.893 bn = 33.16% of pharmaceutical business revenue => 29,834 Derived from two reported figures (innovative drugs and their share) |
| 夏尔 | 2000 | 500 | – | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2001 | 600 | 20.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 600 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2002 | 800 | 33.3 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 800 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2003 | 1000 | 25.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2004 | 1300 | 30.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2005 | 1500 | 15.4 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2006 | 1700 | 13.3 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2007 | 1800 | 5.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2008 | 2000 | 11.1 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2009 | 2400 | 20.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2010 | 2700 | 12.5 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2011 | 3500 | 29.6 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2012 | 4700 | 34.3 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total revenues (pure-play pharma; Shire Pharmaceuticals G...Total revenues (pure-play pharma; Shire Pharmaceuticals Group)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4700 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 夏尔 | 2013 | 4847 | 3.1 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shire ... 4,847" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 夏尔 | 2014 | 5830 | 20.3 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shire ... 5,830" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 夏尔 | 2015 | 6100 | 4.6 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shire ... 6,100" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 夏尔 | 2016 | 10886 | 78.5 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shire ... 10,886" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 夏尔 | 2017 | 14449 | 32.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shire ... 14,449" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 夏尔 | 2018 | 14993 | 3.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Shire ... 14,993" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 大冢 | 2002 | 2686 | – | C | 327,129 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 474,100 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2003 | 2991 | 11.4 | C | 337,203 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 488,700 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2004 | 4392 | 46.8 | C | 471,822 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 683,800 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2005 | 4596 | 4.6 | C | 519,639 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 753,100 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2006 | 5039 | 9.6 | C | 589,191 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 853,900 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2007 | 5627 | 11.7 | C | 640,596 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 928,400 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2008 | 6591 | 17.1 | C | 659,571 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 955,900 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2009 | 8066 | 22.4 | C | 748,161 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 1,084,291 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2010 | 9103 | 12.9 | C | 778,036 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 1,127,589 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2011 | 10096 | 10.9 | C | 796,655 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Prescription pharmaceutical revenue estimate = group net ...Prescription pharmaceutical revenue estimate = group net sales x 0.69group net sales 1,154,573 x 0.69 Share 0.69 calibrated to the Pharm Exec 2014 row for FY2012/13 (8,655 US$ m x 97.6 = 845 bn / 1,218 bn). The group includes Pocari Sweat, nutraceuticals and consumer goods; the Rx share before the 2008-2010 holding structure was probably different. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大冢 | 2012 | 8655 | -14.3 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka ... 8,655" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 大冢 | 2014 | 6961 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka ... 6,961" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 大冢 | 2015 | 6728 | -3.3 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka ... 6,728" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 大冢 | 2016 | 5389 | -19.9 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka ... 5,389" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 大冢 | 2017 | 5324 | -1.2 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka ... 5,324" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 大冢 | 2018 | 5726 | 7.6 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka ... 5,726" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 大冢 | 2019 | 6711 | 17.2 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Otsuka Holdings ... 6,711" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 大冢 | 2020 | 7219 | 7.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 大冢 | 2021 | 7368 | 2.1 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 大冢 | 2022 | 7357 | -0.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 大冢 | 2023 | 7970 | 8.3 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 大冢 | 2024 | 8975 | 12.6 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 大冢 | 2025 | 9869 | 10.0 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 大日本制药 | 2000 | 1223 | – | C | 135,065 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85group net sales 158,900 x 0.85 Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大日本制药 | 2001 | 1117 | -8.7 | C | 139,499 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85group net sales 164,117 x 0.85 Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大日本制药 | 2002 | 1202 | 7.6 | C | 146,337 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85group net sales 172,161 x 0.85 Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大日本制药 | 2003 | 1288 | 7.2 | C | 145,216 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85group net sales 170,842 x 0.85 Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 大日本制药 | 2004 | 1376 | 6.8 | C | 147,814 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.85group net sales 173,899 x 0.85 Dainippon Pharmaceutical also had food, chemicals and diagnostics; 85% assumed. Values of the page for code 4506 before the Oct 2005 merger with Sumitomo Pharmaceuticals. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 天士力 | 2000 | 47 | – | B | 392 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 39,158.28" (10,000 CNY) = 391.58 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2001 | 83 | 74.9 | B | 685 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 68,456.88" (10,000 CNY) = 684.57 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2002 | 112 | 35.8 | B | 930 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 92,979.17" (10,000 CNY) = 929.79 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2003 | 128 | 13.6 | B | 1,056 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 105,580.53" (10,000 CNY) = 1,055.81 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2004 | 157 | 23.3 | B | 1,302 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 130,177.76" (10,000 CNY) = 1,301.78 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2005 | 179 | 13.8 | B | 1,466 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 146,608.38" (10,000 CNY) = 1,466.08 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2006 | 303 | 69.5 | B | 2,417 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"主营业务收入 241,708.70" (10,000 CNY) = 2,417.09 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2007 | 368 | 21.2 | B | 2,795 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 279,490.58" (10,000 CNY) = 2,794.91 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2008 | 494 | 34.5 | B | 3,434 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 343,421.55" (10,000 CNY) = 3,434.22 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2009 | 585 | 18.2 | B | 3,993 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 399,264.53" (10,000 CNY) = 3,992.65 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2010 | 687 | 17.6 | B | 4,652 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 465,159.11" (10,000 CNY) = 4,651.59 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2011 | 1017 | 47.9 | B | 6,570 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 656,966.46" (10,000 CNY) = 6,569.66 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2012 | 1475 | 45.0 | B | 9,301 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 930,145.58" (10,000 CNY) = 9,301.46 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2013 | 1807 | 22.5 | B | 11,108 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 1,110,806.59" (10,000 CNY) = 11,108.07 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2014 | 2042 | 13.0 | B | 12,578 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 1,257,770.15" (10,000 CNY) = 12,577.70 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2015 | 2106 | 3.1 | B | 13,228 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 1,322,751.22" (10,000 CNY) = 13,227.51 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2016 | 2100 | -0.2 | B | 13,946 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 1,394,549.70" (10,000 CNY) = 13,945.50 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2017 | 2383 | 13.4 | B | 16,094 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入/营业收入 1,609,415.00" (10,000 CNY) = 16,094.15 m Sina Finance table for stock 600535. Pre-2007 line is main business revenue. |
| 天士力 | 2018 | 2725 | 14.3 | B | 17,990 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 179.90亿元" = 17990 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2019 | 2752 | 1.0 | B | 18,998 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 189.98亿元" = 18998 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2020 | 1969 | -28.4 | B | 13,576 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 135.76亿元" = 13576 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2021 | 1233 | -37.4 | B | 7,952 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 79.52亿元" = 7952 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2022 | 1286 | 4.3 | B | 8,637 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 86.37亿元" = 8637 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2023 | 1226 | -4.7 | B | 8,674 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 86.74亿元" = 8674 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2024 | 1181 | -3.7 | B | 8,498 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 84.98亿元" = 8498 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 天士力 | 2025 | 1146 | -3.0 | B | 8,236 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (own drugs plus some ...Total revenue of the listed company (own drugs plus some commercial sales)"营业总收入 82.36亿元" = 8236 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 太阳制药 | 2001 | 157 | – | B | 7,505 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 7,505 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2002 | 201 | 27.7 | B | 9,725 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 9,725 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2003 | 214 | 6.7 | B | 9,847 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 9,847 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2004 | 267 | 24.7 | B | 11,983 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 11,983 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2005 | 393 | 47.2 | B | 17,372 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 17,372 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2006 | 496 | 26.1 | B | 22,373 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 22,373 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2007 | 863 | 73.9 | B | 34,606 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 34,606 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2008 | 959 | 11.1 | B | 43,751 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 43,751 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2009 | 805 | -16.1 | B | 38,086 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 38,086 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2010 | 1258 | 56.3 | B | 57,214 INR m | phx_sun_ar+fx_fed_h10 | Annual report 2010-11, ten-year highlights | Consolidated income from operations (pharma)Consolidated income from operations (pharma)Income from Operations 57,214 (Rs m) Read through a search summary of the 2010-11 annual report; the PDF itself not opened. FY2009 includes Taro, FY2010 does not (deconsolidated). FY2008 matches a separate release (34,605.6). |
| 太阳制药 | 2012 | 2311 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma ... 2,311" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 太阳制药 | 2014 | 5012 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma ... 5,012" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 太阳制药 | 2015 | 4503 | -10.2 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma ... 4,503" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 太阳制药 | 2016 | 4804 | 6.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma ... 4,804" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 太阳制药 | 2017 | 4147 | -13.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma ... 4,147" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 太阳制药 | 2018 | 4222 | 1.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma ... 4,222" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 太阳制药 | 2019 | 4658 | 10.3 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sun Pharma Industries ... 4,658" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 太阳制药 | 2020 | 4630 | -0.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 太阳制药 | 2021 | 5091 | 10.0 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 太阳制药 | 2022 | 5424 | 6.5 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 太阳制药 | 2023 | 5789 | 6.7 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 太阳制药 | 2024 | 6081 | 5.0 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 太阳制药 | 2025 | 6441 | 5.9 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 安万特 | 2000 | 12281 | – | C | 13,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur v...Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 安万特 | 2001 | 12985 | 5.7 | C | 14,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur v...Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 安万特 | 2002 | 15881 | 22.3 | C | 16,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur v...Aventis pharmaceutical sales (Rx, incl. Aventis Pasteur vaccines; Aventis CropScience and Behring excluded)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 安斯泰来 | 2005 | 7777 | – | B | 879,361 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 879,361 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2006 | 7873 | 1.2 | B | 920,624 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 920,624 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2007 | 8543 | 8.5 | B | 972,586 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 972,586 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2008 | 9650 | 13.0 | B | 965,698 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 965,698 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2009 | 10511 | 8.9 | B | 974,877 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 974,877 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2010 | 11161 | 6.2 | B | 953,947 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 953,947 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2011 | 12285 | 10.1 | B | 969,387 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all prescription pharma)Consolidated net sales (practically all prescription pharma)consolidated net sales 969,387 Astellas formed April 2005 (Yamanouchi + Fujisawa); FY ending March 2006 is the first year with both. Consistent with the Pharm Exec 2014 row for FY2012/13 (10,431 US$ m x 97.6 = 1,018 bn vs 1,006 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 安斯泰来 | 2012 | 10431 | -15.1 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas ... 10,431" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 安斯泰来 | 2014 | 10419 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas ... 10,419" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 安斯泰来 | 2015 | 10937 | 5.0 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas ... 10,937" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 安斯泰来 | 2016 | 11109 | 1.6 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas ... 11,109" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 安斯泰来 | 2017 | 10888 | -2.0 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas ... 10,888" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 安斯泰来 | 2018 | 11036 | 1.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas ... 11,036" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 安斯泰来 | 2019 | 11444 | 3.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Astellas Pharma ... 11,444" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 安斯泰来 | 2020 | 11515 | 0.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 安斯泰来 | 2021 | 11828 | 2.7 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 安斯泰来 | 2022 | 10511 | -11.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 安斯泰来 | 2023 | 10377 | -1.3 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 安斯泰来 | 2024 | 11816 | 13.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 安斯泰来 | 2025 | 12597 | 6.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 安进 | 2000 | 3629 | – | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2001 | 4016 | 10.7 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2002 | 5523 | 37.5 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2003 | 8356 | 51.3 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2004 | 10550 | 26.3 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2005 | 12430 | 17.8 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2006 | 14268 | 14.8 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2007 | 14771 | 3.5 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2008 | 14750 | -0.1 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)14400 / (1-2.4%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 安进 | 2009 | 14400 | -2.4 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)amgen 14.4 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 安进 | 2010 | 15053 | 4.5 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2011 | 15300 | 1.6 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)amgen $15.3 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 安进 | 2012 | 17265 | 12.8 | B | phx_est | selected data / segment note | Total revenues (product sales plus royalties and other)Total revenues (product sales plus royalties and other)Amgen total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 安进 | 2013 | 18192 | 5.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 18,192" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 安进 | 2014 | 19327 | 6.2 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 19,327" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 安进 | 2015 | 20944 | 8.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 20,944" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 安进 | 2016 | 21892 | 4.5 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 21,892" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 安进 | 2017 | 21795 | -0.4 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 21,795" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 安进 | 2018 | 22533 | 3.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 22,533" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 安进 | 2019 | 22204 | -1.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Amgen ... 22,204" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 安进 | 2020 | 24098 | 8.5 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 安进 | 2021 | 23957 | -0.6 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 安进 | 2022 | 22536 | -5.9 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 安进 | 2023 | 26621 | 18.1 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 安进 | 2024 | 31748 | 19.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 安进 | 2025 | 34950 | 10.1 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 小野制药 | 2001 | 1046 | – | C | 130,686 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 133,353 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2002 | 1086 | 3.8 | C | 132,293 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 134,993 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2003 | 1212 | 11.5 | C | 136,595 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 139,383 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2004 | 1326 | 9.4 | C | 142,396 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 145,302 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2005 | 1289 | -2.8 | C | 145,698 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 148,671 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2006 | 1188 | -7.8 | C | 138,877 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 141,711 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2007 | 1256 | 5.7 | C | 142,979 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 145,897 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2008 | 1337 | 6.5 | C | 133,825 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 136,556 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2009 | 1437 | 7.4 | C | 133,266 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 135,986 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2010 | 1551 | 7.9 | C | 132,550 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 135,255 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2011 | 1810 | 16.7 | C | 142,862 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.98group net sales 145,778 x 0.98 Ono is nearly pure-play Rx; 2% assumed for other. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 小野制药 | 2016 | 2153 | – | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ono ... 2,153" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 小野制药 | 2017 | 2363 | 9.8 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ono ... 2,363" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 小野制药 | 2019 | 3266 | – | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ono Pharmaceutical ... 3,266" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 小野制药 | 2020 | 2908 | -11.0 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 山之内制药 | 2001 | 3853 | – | B | 481,300 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)consolidated net sales 481,300 Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 山之内制药 | 2002 | 4160 | 8.0 | B | 506,600 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)consolidated net sales 506,600 Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 山之内制药 | 2003 | 4535 | 9.0 | B | 511,200 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)consolidated net sales 511,200 Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 山之内制药 | 2004 | 4162 | -8.2 | B | 447,100 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準) | Consolidated net sales (Yamanouchi, practically all pharma)Consolidated net sales (Yamanouchi, practically all pharma)consolidated net sales 447,100 Pre-merger values of the page for code 4503 (Yamanouchi Pharmaceutical; the page does not name the entity, inferred from the 2005 merger). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 山德士 | 2023 | 9647 | – | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 山德士 | 2024 | 10357 | 7.4 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 山德士 | 2025 | 11086 | 7.0 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 强生 | 2000 | 9500 | – | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2001 | 11100 | 16.8 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2002 | 13100 | 18.0 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2003 | 15300 | 16.8 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2004 | 17500 | 14.4 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2005 | 20300 | 16.0 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2006 | 23300 | 14.8 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2007 | 24600 | 5.6 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2008 | 24590 | 0.0 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)22500 / (1-8.5%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 强生 | 2009 | 22500 | -8.5 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)jnj 22.5 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 强生 | 2010 | 22400 | -0.4 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2011 | 24400 | 8.9 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)jnj $24.4 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 强生 | 2012 | 25400 | 4.1 | C | phx_est | selected data / segment note | Pharmaceutical segment salesPharmaceutical segment salesJ&J 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 强生 | 2013 | 26475 | 4.2 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson & Johnson ... 26,475" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 强生 | 2014 | 30726 | 16.1 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson & Johnson ... 30,726" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 强生 | 2015 | 29864 | -2.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson & Johnson ... 29,864" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 强生 | 2016 | 31671 | 6.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson & Johnson ... 31,671" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 强生 | 2017 | 34397 | 8.6 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson & Johnson ... 34,397" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 强生 | 2018 | 38815 | 12.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson & Johnson ... 38,815" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 强生 | 2019 | 40083 | 3.3 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Johnson &Johnson ... 40,083" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 强生 | 2020 | 43149 | 7.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 强生 | 2021 | 49821 | 15.5 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 强生 | 2022 | 50179 | 0.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 强生 | 2023 | 53463 | 6.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 强生 | 2024 | 55745 | 4.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 强生 | 2025 | 59331 | 6.4 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 恒瑞医药 | 2000 | 59 | – | B | 489 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 48,876.18" (10,000 CNY) = 488.76 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2001 | 77 | 30.5 | B | 638 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 63,752.23" (10,000 CNY) = 637.52 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2002 | 92 | 18.9 | B | 758 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 75,823.71" (10,000 CNY) = 758.24 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2003 | 127 | 39.0 | B | 1,054 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 105,433.96" (10,000 CNY) = 1,054.34 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2004 | 139 | 9.0 | B | 1,149 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 114,886.91" (10,000 CNY) = 1,148.87 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2005 | 145 | 4.7 | B | 1,191 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 119,057.55" (10,000 CNY) = 1,190.58 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2006 | 179 | 22.9 | B | 1,423 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"主营业务收入 142,345.61" (10,000 CNY) = 1,423.46 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2007 | 258 | 44.3 | B | 1,960 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 195,966.01" (10,000 CNY) = 1,959.66 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2008 | 344 | 33.7 | B | 2,393 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 239,256.12" (10,000 CNY) = 2,392.56 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2009 | 443 | 28.7 | B | 3,029 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 302,896.09" (10,000 CNY) = 3,028.96 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2010 | 553 | 24.7 | B | 3,744 CNY m | phx_hengrui_notes+fx_fed_h10 | broker commentary on the annual report | Total revenue (pharma)Total revenue (pharma)2010A revenue 3,744.11 m Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened. |
| 恒瑞医药 | 2011 | 704 | 27.3 | B | 4,550 CNY m | phx_hengrui_notes+fx_fed_h10 | broker commentary on the annual report | Total revenue (pharma)Total revenue (pharma)2011 revenue 4.550 bn, +21.53% Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened. |
| 恒瑞医药 | 2012 | 862 | 22.4 | B | 5,435 CNY m | phx_hengrui_notes+fx_fed_h10 | broker commentary on the annual report | Total revenue (pharma)Total revenue (pharma)2012 revenue 5.435 bn, +19.44% Figures from broker notes surfaced by search (Eastmoney PDFs); the annual reports on sse.com.cn not opened. |
| 恒瑞医药 | 2013 | 1009 | 17.1 | B | 6,203 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 620,307.44" (10,000 CNY) = 6,203.07 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2014 | 1210 | 19.9 | B | 7,452 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 745,225.31" (10,000 CNY) = 7,452.25 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2015 | 1483 | 22.6 | B | 9,316 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 931,596.02" (10,000 CNY) = 9,315.96 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2016 | 1671 | 12.7 | B | 11,094 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 1,109,372.41" (10,000 CNY) = 11,093.72 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2017 | 2049 | 22.6 | B | 13,836 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入/营业收入 1,383,562.94" (10,000 CNY) = 13,835.63 m Sina Finance table for stock 600276; 2010-2012 values agree with the existing broker-note rows. Pre-2007 line is main business revenue. |
| 恒瑞医药 | 2018 | 2570 | 25.5 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Hengrui ... 2,570" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 恒瑞医药 | 2019 | 3321 | 29.2 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Jiangsu Hengrui Medicine ... 3,321" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 恒瑞医药 | 2020 | 4022 | 21.1 | B | 27,735 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入 277.35亿元" = 27735 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 恒瑞医药 | 2021 | 4017 | -0.1 | B | 25,906 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入 259.06亿元" = 25906 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 恒瑞医药 | 2022 | 3167 | -21.1 | B | 21,275 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入 212.75亿元" = 21275 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 恒瑞医药 | 2023 | 3225 | 1.8 | B | 22,820 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入 228.20亿元" = 22820 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 恒瑞医药 | 2024 | 3889 | 20.6 | B | 27,985 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入 279.85亿元" = 27985 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 恒瑞医药 | 2025 | 4401 | 13.2 | B | 31,629 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (almost entirely phar...Total revenue of the listed company (almost entirely pharmaceutical)"营业总收入 316.29亿元" = 31629 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 惠氏 | 2000 | 10200 | – | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2001 | 10900 | 6.9 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2002 | 11400 | 4.6 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2003 | 12600 | 10.5 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2004 | 13900 | 10.3 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2005 | 15000 | 7.9 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2006 | 16300 | 8.7 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2007 | 17900 | 9.8 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 惠氏 | 2008 | 18300 | 2.2 | C | phx_est | selected data / segment note | Total net revenue less Consumer Healthcare and Animal Hea...Total net revenue less Consumer Healthcare and Animal Health (about 78-80%)Wyeth net revenue 13.3/14.1/14.6/15.9/17.4/18.8/20.4/22.4/22.8 bn (2000-08) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 拜耳 | 2000 | 3601 | – | C | 3,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2001 | 4119 | 14.4 | C | 4,600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2002 | 4916 | 19.3 | C | 5,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2003 | 6338 | 28.9 | C | 5,600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2004 | 7339 | 15.8 | C | 5,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2005 | 7841 | 6.8 | C | 6,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2006 | 11304 | 44.2 | C | 9,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2007 | 14532 | 28.6 | C | 10,600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2008 | 14999 | 3.2 | C | 10,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2009 | 14490 | -3.4 | C | 10,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2010 | 13674 | -5.6 | C | 10,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2011 | 14477 | 5.9 | C | 10,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 10400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2012 | 14150 | -2.3 | C | 11,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | HealthCare segment: Pharmaceuticals (Bayer Schering Pharm...HealthCare segment: Pharmaceuticals (Bayer Schering Pharma from 2006)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 拜耳 | 2013 | 15594 | 10.2 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 15,594" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 拜耳 | 2014 | 16351 | 4.9 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 16,351" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 拜耳 | 2015 | 15558 | -4.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 15,558" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 拜耳 | 2016 | 16886 | 8.5 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 16,886" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 拜耳 | 2017 | 17544 | 3.9 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 17,544" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 拜耳 | 2018 | 18221 | 3.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 18,221" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 拜耳 | 2019 | 18610 | 2.1 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bayer ... 18,610" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 拜耳 | 2020 | 18995 | 2.1 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 拜耳 | 2021 | 20119 | 5.9 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 拜耳 | 2022 | 18898 | -6.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 拜耳 | 2023 | 17663 | -6.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 拜耳 | 2024 | 17710 | 0.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 拜耳 | 2025 | 19188 | 8.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 新基 | 2003 | 271 | – | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2004 | 377 | 39.1 | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2005 | 537 | 42.4 | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2006 | 899 | 67.4 | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2007 | 1406 | 56.4 | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2008 | 2160 | 53.6 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)2600 / (1+20.1%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 新基 | 2009 | 2600 | 20.4 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)celgene 2.6 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 新基 | 2010 | 3626 | 39.5 | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2011 | 4700 | 29.6 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)celgene $4.7 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 新基 | 2012 | 5506 | 17.1 | B | phx_est | selected data / segment note | Total revenueTotal revenueCelgene total revenue Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 新基 | 2013 | 6359 | 15.5 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Celgene ... 6,359" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 新基 | 2014 | 7476 | 17.6 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Celgene ... 7,476" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 新基 | 2015 | 9069 | 21.3 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Celgene ... 9,069" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 新基 | 2016 | 11114 | 22.5 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Celgene ... 11,114" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 新基 | 2017 | 12928 | 16.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Celgene ... 12,928" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 新基 | 2018 | 15238 | 17.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Celgene ... 15,238" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 施维雅 | 2000 | 2216 | – | C | 2,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2001 | 2328 | 5.1 | C | 2,600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2002 | 2647 | 13.7 | C | 2,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2003 | 3395 | 28.3 | C | 3,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2004 | 3980 | 17.2 | C | 3,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2005 | 4232 | 6.3 | C | 3,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2006 | 4647 | 9.8 | C | 3,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2007 | 5347 | 15.0 | C | 3,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2008 | 6029 | 12.8 | C | 4,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2009 | 5434 | -9.9 | C | 3,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2010 | 5178 | -4.7 | C | 3,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2011 | 5707 | 10.2 | C | 4,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2012 | 5403 | -5.3 | C | 4,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Servier Group turnover (private; pharma pure-play)Servier Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 施维雅 | 2013 | 5058 | -6.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Servier ... 5,058" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 施维雅 | 2014 | 5999 | 18.6 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Servier ... 5,999" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 施维雅 | 2015 | 4470 | -25.5 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Servier ... 4,470" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 施维雅 | 2016 | 4167 | -6.8 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 32 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Servier ... 4,167" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 施维雅 | 2017 | 4566 | 9.6 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Servier ... 4,566" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 施维雅 | 2018 | 5103 | 11.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Servier ... 5,103" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 施维雅 | 2019 | 4658 | -8.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"LES LABORATOIRES SERVIER ... 4,658" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 施维雅 | 2020 | 5155 | 10.7 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 施维雅 | 2021 | 4344 | -15.7 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 施维雅 | 2022 | 5193 | 19.5 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 施维雅 | 2023 | 5113 | -1.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 施维雅 | 2024 | 5262 | 2.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 施维雅 | 2025 | 5440 | 3.4 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 明治制果药业 | 2019 | 6353 | – | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Meiji Holdings ... 6,353" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 晖致 | 2020 | 11495 | – | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 晖致 | 2021 | 17508 | 52.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 晖致 | 2022 | 15999 | -8.6 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 晖致 | 2023 | 15228 | -4.8 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 晖致 | 2024 | 14534 | -4.6 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 晖致 | 2025 | 14090 | -3.1 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 普渡制药 | 2013 | 2217 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Purdue ... 2,217" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 普瑞高 | 2022 | 5436 | – | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 梯瓦 | 2000 | 1200 | – | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2001 | 1700 | 41.7 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2002 | 2500 | 47.1 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2003 | 3300 | 32.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2004 | 3900 | 18.2 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3900 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2005 | 5300 | 35.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2006 | 8400 | 58.5 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8400 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2007 | 9400 | 11.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9400 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2008 | 11100 | 18.1 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11100 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2009 | 13900 | 25.2 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13900 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2010 | 16100 | 15.8 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16100 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2011 | 18300 | 13.7 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2012 | 20300 | 10.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Net revenues (generic + branded pharma)Net revenues (generic + branded pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 梯瓦 | 2013 | 17563 | -13.5 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva ... 17,563" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 梯瓦 | 2014 | 17474 | -0.5 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva ... 17,474" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 梯瓦 | 2015 | 16982 | -2.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva ... 16,982" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 梯瓦 | 2016 | 18462 | 8.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva ... 18,462" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 梯瓦 | 2017 | 18261 | -1.1 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva ... 18,261" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 梯瓦 | 2018 | 13122 | -28.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva ... 13,122" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 梯瓦 | 2019 | 11090 | -15.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Teva Pharmaceutical Industries ... 11,090" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 梯瓦 | 2020 | 11009 | -0.7 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 梯瓦 | 2021 | 10468 | -4.9 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 梯瓦 | 2022 | 12071 | 15.3 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 梯瓦 | 2023 | 12500 | 3.6 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 梯瓦 | 2024 | 13495 | 8.0 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 梯瓦 | 2025 | 14077 | 4.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 森林实验室 | 2008 | 3460 | – | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)3600 / (1+3.9%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 森林实验室 | 2009 | 3600 | 4.0 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)forest 3.6 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Forest fiscal year to March |
|
| 森林实验室 | 2011 | 4200 | – | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)forest $4.2 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn; Forest fiscal year to March |
|
| 森林实验室 | 2013 | 3380 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Forest Laboratories ... 3,380" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 欧加隆 | 2021 | 6172 | – | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 欧加隆 | 2022 | 6038 | -2.2 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 欧加隆 | 2023 | 6142 | 1.7 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 欧加隆 | 2024 | 6219 | 1.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 欧加隆 | 2025 | 6060 | -2.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 武田 | 2000 | 7504 | – | C | 828,524 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 963,400 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2001 | 6919 | -7.8 | C | 864,352 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,005,060 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2002 | 7387 | 6.8 | C | 899,630 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,046,081 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2003 | 8288 | 12.2 | C | 934,331 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,086,431 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2004 | 9035 | 9.0 | B | 970,500 JPY m | phx_takeda_seg+fx_fed_h10 | FY2005 (Mar 2005) results, segment split | Pharmaceutical business net sales (iyaku jigyo)Pharmaceutical business net sales (iyaku jigyo)Pharmaceutical 970.5 bn yen (86%), other 152.5 bn (14%); total 1,122,960 Segment figure as quoted in a web-search result for the FY2005 results announcement; the announcement itself not opened. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2005 | 9220 | 2.1 | C | 1,042,498 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,212,207 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2006 | 9599 | 4.1 | C | 1,122,444 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,305,167 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2007 | 10385 | 8.2 | C | 1,182,330 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,374,802 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2008 | 13220 | 27.3 | C | 1,322,969 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,538,336 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2009 | 13592 | 2.8 | C | 1,260,730 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,465,965 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2010 | 14282 | 5.1 | C | 1,220,671 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,419,385 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2011 | 16445 | 15.1 | C | 1,297,682 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical (Rx) revenue estimate = consolidated net s...Pharmaceutical (Rx) revenue estimate = consolidated net sales x 0.86group net sales 1,508,932 x 0.86 Share 0.86 = pharmaceutical segment share in FY2004/05 (970.5/1,123.0 bn yen), and what the Pharm Exec 2014 row implies for FY2012/13 (13,591 US$ m x ~97.6 yen / 1,557 bn = 0.85). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 武田 | 2012 | 13591 | -17.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 13,591" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 武田 | 2014 | 13038 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 13,038" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 武田 | 2015 | 12565 | -3.6 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 12,565" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 武田 | 2016 | 12773 | 1.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 12,773" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 武田 | 2017 | 13577 | 6.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 13,577" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 武田 | 2018 | 17427 | 28.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 17,427" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 武田 | 2019 | 29747 | 70.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Takeda ... 29,747" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 武田 | 2020 | 27896 | -6.2 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 武田 | 2021 | 29605 | 6.1 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 武田 | 2022 | 29690 | 0.3 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 武田 | 2023 | 27687 | -6.7 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 武田 | 2024 | 29782 | 7.6 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 武田 | 2025 | 29671 | -0.4 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 沃森制药 | 2008 | 1770 | – | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)2000 / (1+13.1%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 沃森制药 | 2009 | 2000 | 13.0 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)watson 2.0 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 沃森制药 | 2011 | 3700 | – | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)watson $3.7 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 法玛西亚 | 2000 | 15000 | – | C | phx_est | selected data / segment note | Pharmaceutical sales (Pharmacia incl. Searle; merged into...Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)Pharmacia sales excl. consumer healthcare and animal health, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 法玛西亚 | 2001 | 14300 | -4.7 | C | phx_est | selected data / segment note | Pharmaceutical sales (Pharmacia incl. Searle; merged into...Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)Pharmacia sales excl. consumer healthcare and animal health, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 法玛西亚 | 2002 | 13800 | -3.5 | C | phx_est | selected data / segment note | Pharmaceutical sales (Pharmacia incl. Searle; merged into...Pharmaceutical sales (Pharmacia incl. Searle; merged into Pfizer Apr 2003)Pharmacia sales excl. consumer healthcare and animal health, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 浙江医药 | 2000 | 133 | – | B | 1,104 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 110,449.29" (10,000 CNY) = 1,104.49 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2001 | 105 | -21.3 | B | 869 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 86,862.82" (10,000 CNY) = 868.63 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2002 | 135 | 28.6 | B | 1,117 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 111,701.21" (10,000 CNY) = 1,117.01 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2003 | 138 | 1.9 | B | 1,138 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 113,847.14" (10,000 CNY) = 1,138.47 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2004 | 168 | 21.8 | B | 1,387 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 138,682.97" (10,000 CNY) = 1,386.83 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2005 | 231 | 37.7 | B | 1,890 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 189,001.58" (10,000 CNY) = 1,890.02 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2006 | 276 | 19.6 | B | 2,199 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"主营业务收入 219,922.61" (10,000 CNY) = 2,199.23 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2007 | 290 | 5.3 | B | 2,209 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 220,882.56" (10,000 CNY) = 2,208.83 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2008 | 542 | 86.4 | B | 3,761 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 376,102.93" (10,000 CNY) = 3,761.03 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2009 | 612 | 13.1 | B | 4,184 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 418,374.08" (10,000 CNY) = 4,183.74 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2010 | 673 | 10.0 | B | 4,558 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 455,826.52" (10,000 CNY) = 4,558.27 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2011 | 747 | 10.9 | B | 4,826 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 482,596.84" (10,000 CNY) = 4,825.97 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2012 | 834 | 11.7 | B | 5,264 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 526,400.61" (10,000 CNY) = 5,264.01 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2013 | 802 | -3.8 | B | 4,933 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 493,292.02" (10,000 CNY) = 4,932.92 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2014 | 784 | -2.2 | B | 4,832 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 483,229.18" (10,000 CNY) = 4,832.29 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2015 | 716 | -8.8 | B | 4,497 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 449,666.24" (10,000 CNY) = 4,496.66 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2016 | 795 | 11.1 | B | 5,279 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 527,920.40" (10,000 CNY) = 5,279.20 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2017 | 843 | 6.0 | B | 5,693 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入/营业收入 569,258.04" (10,000 CNY) = 5,692.58 m Sina Finance table for stock 600216. Mostly bulk APIs and vitamins; counted as pharmaceutical. |
| 浙江医药 | 2018 | 1039 | 23.3 | B | 6,859 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 68.59亿元" = 6859 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2019 | 1020 | -1.8 | B | 7,044 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 70.44亿元" = 7044 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2020 | 1063 | 4.2 | B | 7,327 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 73.27亿元" = 7327 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2021 | 1415 | 33.2 | B | 9,129 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 91.29亿元" = 9129 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2022 | 1208 | -14.6 | B | 8,116 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 81.16亿元" = 8116 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2023 | 1102 | -8.8 | B | 7,794 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 77.94亿元" = 7794 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2024 | 1303 | 18.3 | B | 9,375 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 93.75亿元" = 9375 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 浙江医药 | 2025 | 1236 | -5.2 | B | 8,881 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company (APIs, vitamins, form...Total revenue of the listed company (APIs, vitamins, formulations)"营业总收入 88.81亿元" = 8881 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2000 | 63 | – | B | 518 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2000-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 51,823.65" (10,000 CNY) = 518.24 m Sina Finance table for stock 600267. |
| 海正药业 | 2001 | 70 | 11.6 | B | 578 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2001-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 57,821.17" (10,000 CNY) = 578.21 m Sina Finance table for stock 600267. |
| 海正药业 | 2002 | 92 | 32.0 | B | 763 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2002-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 76,308.32" (10,000 CNY) = 763.08 m Sina Finance table for stock 600267. |
| 海正药业 | 2003 | 187 | 103.4 | B | 1,552 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2003-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 155,178.61" (10,000 CNY) = 1,551.79 m Sina Finance table for stock 600267. |
| 海正药业 | 2004 | 215 | 14.8 | B | 1,781 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2004-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 178,075.12" (10,000 CNY) = 1,780.75 m Sina Finance table for stock 600267. |
| 海正药业 | 2005 | 234 | 8.6 | B | 1,914 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2005-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 191,357.52" (10,000 CNY) = 1,913.58 m Sina Finance table for stock 600267. |
| 海正药业 | 2006 | 286 | 22.5 | B | 2,280 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 主营业务收入, column 2006-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"主营业务收入 228,026.78" (10,000 CNY) = 2,280.27 m Sina Finance table for stock 600267. |
| 海正药业 | 2007 | 373 | 30.5 | B | 2,839 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 283,877.07" (10,000 CNY) = 2,838.77 m Sina Finance table for stock 600267. |
| 海正药业 | 2008 | 458 | 22.7 | B | 3,182 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 318,197.83" (10,000 CNY) = 3,181.98 m Sina Finance table for stock 600267. |
| 海正药业 | 2009 | 586 | 27.9 | B | 4,003 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 400,347.04" (10,000 CNY) = 4,003.47 m Sina Finance table for stock 600267. |
| 海正药业 | 2010 | 671 | 14.6 | B | 4,545 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 454,450.90" (10,000 CNY) = 4,544.51 m Sina Finance table for stock 600267. |
| 海正药业 | 2011 | 799 | 19.0 | B | 5,161 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 516,139.42" (10,000 CNY) = 5,161.39 m Sina Finance table for stock 600267. |
| 海正药业 | 2012 | 920 | 15.2 | B | 5,802 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 580,176.61" (10,000 CNY) = 5,801.77 m Sina Finance table for stock 600267. |
| 海正药业 | 2013 | 1400 | 52.2 | B | 8,604 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 860,431.16" (10,000 CNY) = 8,604.31 m Sina Finance table for stock 600267. |
| 海正药业 | 2014 | 1639 | 17.1 | B | 10,097 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 1,009,674.79" (10,000 CNY) = 10,096.75 m Sina Finance table for stock 600267. |
| 海正药业 | 2015 | 1396 | -14.9 | B | 8,767 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 876,742.81" (10,000 CNY) = 8,767.43 m Sina Finance table for stock 600267. |
| 海正药业 | 2016 | 1466 | 5.0 | B | 9,733 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 973,342.35" (10,000 CNY) = 9,733.42 m Sina Finance table for stock 600267. |
| 海正药业 | 2017 | 1565 | 6.8 | B | 10,572 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入/营业收入 1,057,152.67" (10,000 CNY) = 10,571.53 m Sina Finance table for stock 600267. |
| 海正药业 | 2018 | 1543 | -1.4 | B | 10,187 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 101.87亿元" = 10187 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2019 | 1604 | 3.9 | B | 11,072 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 110.72亿元" = 11072 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2020 | 1647 | 2.7 | B | 11,354 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 113.54亿元" = 11354 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2021 | 1794 | 9.0 | B | 11,572 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 115.72亿元" = 11572 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2022 | 1694 | -5.6 | B | 11,379 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 113.79亿元" = 11379 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2023 | 1421 | -16.1 | B | 10,053 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 100.53亿元" = 10053 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2024 | 1437 | 1.1 | B | 10,340 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 103.40亿元" = 10340 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 海正药业 | 2025 | 1468 | 2.2 | B | 10,550 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Zhejiang Hisun Pharma...Total revenue of the listed company Zhejiang Hisun Pharmaceutical"营业总收入 105.50亿元" = 10550 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 渤健 | 2008 | 2840 | – | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)3200 / (1+12.6%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 渤健 | 2009 | 3200 | 12.7 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)biogen 3.2 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 渤健 | 2011 | 3800 | – | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)biogen $3.8 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 渤健 | 2013 | 5429 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 5,429" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 渤健 | 2014 | 8203 | 51.1 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 8,203" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 渤健 | 2015 | 9189 | 12.0 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 9,189" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 渤健 | 2016 | 9818 | 6.8 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 9,818" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 渤健 | 2017 | 10355 | 5.5 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 10,355" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 渤健 | 2018 | 10887 | 5.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 10,887" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 渤健 | 2019 | 11380 | 4.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Biogen ... 11,380" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 渤健 | 2020 | 10692 | -6.0 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 渤健 | 2021 | 8847 | -17.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 渤健 | 2022 | 7988 | -9.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 渤健 | 2023 | 7247 | -9.3 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 渤健 | 2024 | 7215 | -0.4 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 渤健 | 2025 | 7119 | -1.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 灵北 | 2000 | 297 | – | C | 2,400 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2001 | 372 | 25.2 | C | 3,100 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3100 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2002 | 458 | 23.0 | C | 3,600 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3600 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2003 | 655 | 43.0 | C | 4,300 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4300 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2004 | 836 | 27.7 | C | 5,000 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5000 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2005 | 1002 | 19.9 | C | 6,000 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6000 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2006 | 1196 | 19.3 | C | 7,100 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7100 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2007 | 1509 | 26.2 | C | 8,200 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 8200 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2008 | 1913 | 26.8 | C | 9,700 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 9700 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2009 | 2208 | 15.4 | C | 11,800 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11800 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2010 | 2442 | 10.6 | C | 13,700 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 13700 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2011 | 2914 | 19.3 | C | 15,600 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15600 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2012 | 2938 | 0.8 | C | 17,000 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total revenue (pure-play pharma)Total revenue (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17000 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 灵北 | 2013 | 2431 | -17.2 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Lundbeck ... 2,431" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 灵北 | 2014 | 2223 | -8.6 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Lundbeck ... 2,223" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 爱可泰隆 | 2016 | 2448 | – | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Actelion ... 2,448" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 爵士制药 | 2021 | 3079 | – | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 爵士制药 | 2022 | 3634 | 18.0 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 爵士制药 | 2023 | 3737 | 2.8 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 爵士制药 | 2024 | 3821 | 2.2 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 爵士制药 | 2025 | 4022 | 5.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 瑞迪博士实验室 | 2007 | 1247 | – | B | 50,006 INR m | phx_drl_20f+fx_fed_h10 | Form 20-F FY2012, selected data (IFRS) | Total revenues (IFRS)Total revenues (IFRS)revenues 50,006 (Rs m) Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business. |
| 瑞迪博士实验室 | 2008 | 1522 | 22.0 | B | 69,441 INR m | phx_drl_20f+fx_fed_h10 | Form 20-F FY2012, selected data (IFRS) | Total revenues (IFRS)Total revenues (IFRS)revenues 69,441 (Rs m) Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business. |
| 瑞迪博士实验室 | 2009 | 1485 | -2.4 | B | 70,277 INR m | phx_drl_20f+fx_fed_h10 | Form 20-F FY2012, selected data (IFRS) | Total revenues (IFRS)Total revenues (IFRS)revenues 70,277 (Rs m) Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business. |
| 瑞迪博士实验室 | 2010 | 1642 | 10.6 | B | 74,693 INR m | phx_drl_20f+fx_fed_h10 | Form 20-F FY2012, selected data (IFRS) | Total revenues (IFRS)Total revenues (IFRS)revenues 74,693 (Rs m) Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business. |
| 瑞迪博士实验室 | 2011 | 2029 | 23.5 | B | 96,737 INR m | phx_drl_20f+fx_fed_h10 | Form 20-F FY2012, selected data (IFRS) | Total revenues (IFRS)Total revenues (IFRS)revenues 96,737 (Rs m) Year-to-value mapping read through a search summary; check against the FY2010/11 20-Fs. Includes a small services business. |
| 瑞迪博士实验室 | 2023 | 3007 | – | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 瑞迪博士实验室 | 2024 | 3304 | 9.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 田边三菱制药 | 2005 | 3607 | – | B | 407,800 JPY m | phx_mtpc+fx_fed_h10 | article text | Combined sales of Mitsubishi Pharma + Tanabe Seiyaku (pro...Combined sales of Mitsubishi Pharma + Tanabe Seiyaku (pro forma, practically all pharma)combined sales totaled 407.8 billion yen in the year to March 2006 Seen only as a search snippet; the two merged in Oct 2007. |
| 田边三菱制药 | 2011 | 5160 | – | B | 407,156 JPY m | phx_mtpc_credit+fx_fed_h10 | credit report text | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)Yen 419,179 million, 3% up from Yen 407,156 million in the previous term Third-party credit report (snippet); FY2007-2010 not found. |
| 田边三菱制药 | 2012 | 3505 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe ... 3,505" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 田边三菱制药 | 2014 | 2928 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe ... 2,928" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 田边三菱制药 | 2015 | 2542 | -13.2 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe ... 2,542" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 田边三菱制药 | 2016 | 2696 | 6.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe ... 2,696" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 田边三菱制药 | 2017 | 2581 | -4.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe ... 2,581" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 田边三菱制药 | 2018 | 2913 | 12.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe ... 2,913" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 田边三菱制药 | 2019 | 2822 | -3.1 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mitsubishi Tanabe Pharma ... 2,822" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 田边三菱制药 | 2020 | 3106 | 10.1 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 百时美施贵宝 | 2000 | 13000 | – | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2001 | 14000 | 7.7 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2002 | 14200 | 1.4 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2003 | 15200 | 7.0 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2004 | 14600 | -3.9 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2005 | 14500 | -0.7 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2006 | 14900 | 2.8 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2007 | 15900 | 6.7 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2008 | 17690 | 11.3 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)18800 / (1+6.3%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 百时美施贵宝 | 2009 | 18800 | 6.3 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)bms 18.8 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 百时美施贵宝 | 2010 | 19500 | 3.7 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2011 | 21200 | 8.7 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)bms $21.2 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 百时美施贵宝 | 2012 | 17600 | -17.0 | C | phx_est | selected data / segment note | Pharmaceuticals segment (excl. nutritionals, medical imag...Pharmaceuticals segment (excl. nutritionals, medical imaging, ConvaTec)BMS segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 百时美施贵宝 | 2013 | 12306 | -30.1 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 12,306" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 百时美施贵宝 | 2014 | 11969 | -2.7 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 11,969" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 百时美施贵宝 | 2015 | 14480 | 21.0 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 14,480" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 百时美施贵宝 | 2016 | 18163 | 25.4 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 18,163" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 百时美施贵宝 | 2017 | 19258 | 6.0 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 19,258" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 百时美施贵宝 | 2018 | 21581 | 12.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 21,581" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 百时美施贵宝 | 2019 | 40689 | 88.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Bristol-Myers Squibb ... 40,689" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 百时美施贵宝 | 2020 | 41903 | 3.0 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 百时美施贵宝 | 2021 | 45669 | 9.0 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 百时美施贵宝 | 2022 | 45417 | -0.6 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 百时美施贵宝 | 2023 | 44398 | -2.2 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 百时美施贵宝 | 2024 | 47821 | 7.7 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 百时美施贵宝 | 2025 | 47748 | -0.2 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 百济神州 | 2024 | 3789 | – | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 百济神州(BeOne) | 2025 | 5282 | – | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 百深(Baxalta) | 2015 | 6148 | – | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 29 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Baxalta ... 6,148" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 百特 | 2008 | 5320 | – | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)5600 / (1+5.2%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 百特 | 2009 | 5600 | 5.3 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)baxter 5.6 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 百特 | 2011 | 6100 | – | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)baxter $6.1 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 百特 | 2013 | 8265 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Baxter ... 8,265" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 百特 | 2014 | 8694 | 5.2 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Baxter ... 8,694" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 益普生 | 2018 | 2628 | – | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ipsen ... 2,628" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 益普生 | 2019 | 2884 | 9.7 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ipsen ... 2,884" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 益普生 | 2020 | 2962 | 2.7 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 益普生 | 2021 | 3236 | 9.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 益普生 | 2022 | 3447 | 6.5 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 益普生 | 2023 | 3555 | 3.1 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 益普生 | 2024 | 3708 | 4.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 益普生 | 2025 | 4155 | 12.1 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 盐野义制药 | 2003 | 1707 | – | C | 192,384 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 200,400 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2004 | 1781 | 4.4 | C | 191,328 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 199,300 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2005 | 1667 | -6.4 | C | 188,448 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 196,300 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2006 | 1639 | -1.6 | C | 191,712 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 199,700 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2007 | 1807 | 10.2 | C | 205,697 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 214,268 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2008 | 2182 | 20.8 | C | 218,411 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 227,511 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2009 | 2883 | 32.1 | C | 267,362 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 278,502 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2010 | 3171 | 10.0 | C | 271,056 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 282,350 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 盐野义制药 | 2011 | 3252 | 2.5 | C | 256,584 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Pharmaceutical revenue estimate = consolidated net sales ...Pharmaceutical revenue estimate = consolidated net sales x 0.96group net sales 267,275 x 0.96 Small non-pharma businesses (diagnostics, chemicals, OTC) assumed at 4%. FY2010 includes the step-up in ViiV royalty income. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 石药集团 | 2009 | 774 | – | C | 6,000 HKD m | phx_cn_cspc+phx_cn_est+fx_fed_h10 | Financial Summary (p.120) | Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)Listed vehicle revenue HK$ 1,296.3 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C. |
| 石药集团 | 2010 | 850 | 9.8 | C | 6,600 HKD m | phx_cn_cspc+phx_cn_est+fx_fed_h10 | Financial Summary (p.120) | Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)Listed vehicle revenue HK$ 1,757.6 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C. |
| 石药集团 | 2011 | 964 | 13.4 | C | 7,500 HKD m | phx_cn_cspc+phx_cn_est+fx_fed_h10 | Financial Summary (p.120) | Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)Listed vehicle revenue HK$ 2,407.4 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C. |
| 石药集团 | 2012 | 1109 | 15.1 | C | 8,600 HKD m | phx_cn_cspc+phx_cn_est+fx_fed_h10 | Financial Summary (p.120) | Estimated revenue of the full CSPC pharmaceutical group (...Estimated revenue of the full CSPC pharmaceutical group (HK$)Listed vehicle revenue HK$ 4,146.4 m (before the late-2012 injection of the parent's Shijiazhuang businesses); 2013 group = 9,949 m, back-cast at roughly 10-15% a year The AR2012/AR2014 summaries show only the small listed vehicle (HK$1.3-4.1 bn, marked 'Note') for 2009-2012; the operating group was much larger, so a back-cast from 2013 is used. Replace with CSPC Holdings / Shijiazhuang Pharma Group figures if found. Grade C. |
| 石药集团 | 2013 | 1283 | 15.7 | B | 9,949 HKD m | phx_cn_cspc+fx_fed_h10 | Financial Summary | Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)Revenue 9,949,103 (HK$'000) HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified. |
| 石药集团 | 2014 | 1413 | 10.1 | B | 10,955 HKD m | phx_cn_cspc+fx_fed_h10 | Financial Summary | Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)Revenue 10,955,077 (HK$'000) HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified. |
| 石药集团 | 2015 | 1470 | 4.0 | B | 11,394 HKD m | phx_cn_cspc+fx_fed_h10 | consolidated statement of profit or loss, 2015 comparative (via search summary) | Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)Revenue HK$11,393.7 m HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified. |
| 石药集团 | 2016 | 1593 | 8.4 | B | 12,369 HKD m | phx_cn_cspc+fx_fed_h10 | consolidated statement of profit or loss (via search summary) | Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)Revenue HK$12,369.0 m HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified. |
| 石药集团 | 2017 | 1984 | 24.5 | B | 15,463 HKD m | phx_cn_cspc+fx_fed_h10 | turnover chart in the 2018 report (via search summary) | Revenue (pharmaceutical group, HK$)Revenue (pharmaceutical group, HK$)about HK$15,463 m HK$ reporting currency. 2013 is the first year of the enlarged group (parent businesses injected late 2012); the 2013 comparative was later restated to carve out disposals. 2017 read from a chart, to be verified. |
| 石药集团 | 2018 | 2683 | 35.2 | B | 21,029 HKD m | phx_cn_cspc_res+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)"revenue HK$21,029 million, +36.0%" HK$ as originally reported (restated to RMB 17,716.5 m in the 2019 report) |
| 石药集团 | 2019 | 3201 | 19.3 | B | 22,103 CNY m | phx_cn_cspc_res+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)"Revenue RMB22,103 million, +24.8%" Reporting currency changed to RMB from 2019 |
| 石药集团 | 2020 | 3617 | 13.0 | B | 24,942 CNY m | phx_cn_cspc_res+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)"revenue +12.8% to RMB24,942 million" Annual results |
| 石药集团 | 2021 | 4321 | 19.4 | B | 27,867 CNY m | phx_cn_cspc_res+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)"+11.7% to RMB27,867 million" Matches company filing quoted in search |
| 石药集团 | 2022 | 4606 | 6.6 | B | 30,937 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue FY2022 30,937 Third-party table (S&P Global data) |
| 石药集团 | 2023 | 4445 | -3.5 | B | 31,450 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue FY2023 31,450 Third-party table (S&P Global data) |
| 石药集团 | 2024 | 4032 | -9.3 | B | 29,009 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue FY2024 29,009 Third-party table; another aggregator shows 27,758 |
| 石药集团 | 2025 | 3619 | -10.2 | B | 26,006 CNY m | phx_cn_stockanalysis+fx_fed_h10 | results / financials table | Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue (pharmaceutical group, HK$ to 2018, RMB from 2019)Revenue FY2025 26,006 Third-party table; audited FY2025 results published March 2026 |
| 礼来 | 2000 | 10862 | – | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2001 | 11543 | 6.3 | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2002 | 11078 | -4.0 | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2003 | 12583 | 13.6 | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2004 | 13858 | 10.1 | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2005 | 14645 | 5.7 | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2006 | 15691 | 7.1 | B | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2007 | 17200 | 9.6 | C | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2008 | 19330 | 12.4 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)21200 / (1+9.7%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 礼来 | 2009 | 21200 | 9.7 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)lilly 21.2 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 礼来 | 2010 | 21700 | 2.4 | C | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2011 | 21900 | 0.9 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)lilly $21.9 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 礼来 | 2012 | 20500 | -6.4 | C | phx_est | selected data / segment note | Net sales, pharmaceutical (Elanco animal health excluded ...Net sales, pharmaceutical (Elanco animal health excluded from 2007)Lilly net sales 2000-06 as reported; 2007+ total less Elanco Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 礼来 | 2013 | 20119 | -1.9 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 20,119" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 礼来 | 2014 | 16349 | -18.7 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 16,349" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 礼来 | 2015 | 15792 | -3.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 15,792" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 礼来 | 2016 | 17173 | 8.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 17,173" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 礼来 | 2017 | 18532 | 7.9 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 18,532" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 礼来 | 2018 | 19580 | 5.7 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 13 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 19,580" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 礼来 | 2019 | 20085 | 2.6 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Eli Lilly ... 20,085" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 礼来 | 2020 | 22646 | 12.8 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 礼来 | 2021 | 25958 | 14.6 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 礼来 | 2022 | 25463 | -1.9 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 礼来 | 2023 | 31868 | 25.2 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 礼来 | 2024 | 40716 | 27.8 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 礼来 | 2025 | 60777 | 49.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 福泰制药 | 2018 | 3038 | – | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Vertex ... 3,038" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 福泰制药 | 2019 | 4161 | 37.0 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Vertex Pharmaceuticals ... 4,161" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 福泰制药 | 2020 | 6203 | 49.1 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 福泰制药 | 2021 | 7573 | 22.1 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 福泰制药 | 2022 | 8607 | 13.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 福泰制药 | 2023 | 9869 | 14.7 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 福泰制药 | 2024 | 11020 | 11.7 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 福泰制药 | 2025 | 11971 | 8.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 科伦药业 | 2007 | 267 | – | B | 2,029 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2007-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 202,932.66" (10,000 CNY) = 2,029.33 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2008 | 377 | 41.4 | B | 2,621 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2008-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 262,139.13" (10,000 CNY) = 2,621.39 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2009 | 475 | 25.9 | B | 3,246 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2009-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 324,598.53" (10,000 CNY) = 3,245.99 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2010 | 595 | 25.2 | B | 4,026 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2010-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 402,640.00" (10,000 CNY) = 4,026.40 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2011 | 797 | 33.9 | B | 5,148 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2011-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 514,784.88" (10,000 CNY) = 5,147.85 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2012 | 933 | 17.1 | B | 5,885 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2012-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 588,527.86" (10,000 CNY) = 5,885.28 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2013 | 1111 | 19.1 | B | 6,831 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2013-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 683,128.20" (10,000 CNY) = 6,831.28 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2014 | 1302 | 17.2 | B | 8,023 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2014-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 802,342.13" (10,000 CNY) = 8,023.42 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2015 | 1236 | -5.1 | B | 7,763 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2015-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 776,334.00" (10,000 CNY) = 7,763.34 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2016 | 1290 | 4.4 | B | 8,566 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2016-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 856,594.34" (10,000 CNY) = 8,565.94 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2017 | 1693 | 31.2 | B | 11,435 CNY m | phx_cn_sina+fx_fed_h10 | Sina Finance annual income statement, row 营业总收入/营业收入, column 2017-12-31 (unit 10,000 CNY) | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入/营业收入 1,143,494.88" (10,000 CNY) = 11,434.95 m Sina Finance table for stock 002422 (listed 2010; earlier years are the prospectus years Sina carries). Infusion leader. |
| 科伦药业 | 2018 | 2477 | 46.3 | B | 16,352 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 163.52亿元" = 16352 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2019 | 2554 | 3.1 | B | 17,636 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 176.36亿元" = 17636 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2020 | 2388 | -6.5 | B | 16,464 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 164.64亿元" = 16464 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2021 | 2679 | 12.2 | B | 17,277 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 172.77亿元" = 17277 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2022 | 2834 | 5.8 | B | 19,038 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 190.38亿元" = 19038 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2023 | 3032 | 7.0 | B | 21,454 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 214.54亿元" = 21454 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2024 | 3031 | 0.0 | B | 21,812 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 218.12亿元" = 21812 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 科伦药业 | 2025 | 2576 | -15.0 | B | 18,513 CNY m | phx_cn_10jqka+fx_fed_h10 | annual table, row 营业总收入 | Total revenue of the listed company Sichuan Kelun Pharmac...Total revenue of the listed company Sichuan Kelun Pharmaceutical (infusions, APIs, some agro-chemical sales)"营业总收入 185.13亿元" = 18513 RMB m Same basis as the 2013-2017 rows (total revenue of the listed company); 10jqka annual finance table |
| 第一三共 | 2005 | 8189 | – | B | 925,918 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 925,918 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2006 | 7949 | -2.9 | B | 929,506 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 929,506 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2007 | 7731 | -2.7 | B | 880,120 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 880,120 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2008 | 8415 | 8.9 | B | 842,147 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 842,147 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2009 | 10265 | 22.0 | B | 952,105 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 952,105 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2010 | 11318 | 10.3 | B | 967,365 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 967,365 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2011 | 11896 | 5.1 | B | 938,677 JPY m | phx_shashi+fx_fed_h10 | Table 売上高 (連結, 日本基準), securities-report data | Consolidated net sales (practically all pharma)Consolidated net sales (practically all pharma)consolidated net sales 938,677 FY ending March 2006 is the first year of Daiichi Sankyo (merger Sept 2005). Consistent with the Pharm Exec 2014 row for FY2012/13 (10,268 x 97.6 = 1,002 bn vs 998 bn). Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
| 第一三共 | 2012 | 10268 | -13.7 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 10,268" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 第一三共 | 2014 | 7575 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 7,575" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 第一三共 | 2015 | 7215 | -4.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 7,215" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 第一三共 | 2016 | 7535 | 4.4 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 7,535" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 第一三共 | 2017 | 7358 | -2.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 7,358" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 第一三共 | 2018 | 7033 | -4.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 26 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 7,033" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 第一三共 | 2019 | 7942 | 12.9 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Daiichi Sankyo ... 7,942" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 第一三共 | 2020 | 8029 | 1.1 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 第一三共 | 2021 | 7261 | -9.6 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 第一三共 | 2022 | 7089 | -2.4 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 第一三共 | 2023 | 8091 | 14.1 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 第一三共 | 2024 | 10912 | 34.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 第一三共 | 2025 | 12039 | 10.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 第一制药(日本) | 2002 | 2643 | – | A | 321,926 JPY m | phx_daiichi_20f+fx_fed_h10 | Form 20-F FY2005, consolidated statements of income | Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)net sales 321,926 (yen m) Read from the income statement; the Selected Financial Data section (FY2001-02) not reached. |
| 第一制药(日本) | 2003 | 2865 | 8.4 | A | 322,977 JPY m | phx_daiichi_20f+fx_fed_h10 | Form 20-F FY2005, consolidated statements of income | Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)net sales 322,977 (yen m) Read from the income statement; the Selected Financial Data section (FY2001-02) not reached. |
| 第一制药(日本) | 2004 | 3024 | 5.6 | A | 324,860 JPY m | phx_daiichi_20f+fx_fed_h10 | Form 20-F FY2005, consolidated statements of income | Consolidated net sales (pure-play pharma)Consolidated net sales (pure-play pharma)net sales 324,860 (yen m) Read from the income statement; the Selected Financial Data section (FY2001-02) not reached. |
| 罗氏 | 2000 | 8946 | – | C | 15,100 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15100 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2001 | 10139 | 13.3 | C | 17,100 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17100 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2002 | 12178 | 20.1 | C | 18,900 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18900 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2003 | 13911 | 14.2 | C | 18,700 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18700 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2004 | 16514 | 18.7 | C | 20,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2005 | 19690 | 19.2 | C | 24,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2006 | 23548 | 19.6 | C | 29,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2007 | 28362 | 20.4 | C | 34,000 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 34000 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2008 | 33791 | 19.1 | C | 36,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 36500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2009 | 35345 | 4.6 | C | 38,300 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38300 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2010 | 35096 | -0.7 | C | 36,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 36500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2011 | 37869 | 7.9 | C | 33,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2012 | 37888 | 0.0 | C | 35,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals division sales (excl. Diagnostics)Pharmaceuticals division sales (excl. Diagnostics)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 罗氏 | 2013 | 39143 | 3.3 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 39,143" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 罗氏 | 2014 | 40086 | 2.4 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 40,086" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 罗氏 | 2015 | 38733 | -3.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 38,733" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 罗氏 | 2016 | 39552 | 2.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 39,552" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 罗氏 | 2017 | 41732 | 5.5 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 41,732" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 罗氏 | 2018 | 44552 | 6.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 44,552" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 罗氏 | 2019 | 48247 | 8.3 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Roche ... 48,247" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 罗氏 | 2020 | 47492 | -1.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 罗氏 | 2021 | 49293 | 3.8 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 罗氏 | 2022 | 47909 | -2.8 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 罗氏 | 2023 | 49110 | 2.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 罗氏 | 2024 | 52457 | 6.8 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 罗氏 | 2025 | 57514 | 9.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 美纳里尼 | 2000 | 1016 | – | C | 1,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2001 | 1075 | 5.8 | C | 1,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2002 | 1229 | 14.4 | C | 1,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2003 | 1584 | 28.9 | C | 1,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2004 | 1866 | 17.8 | C | 1,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2005 | 1991 | 6.7 | C | 1,600 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1600 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2006 | 2135 | 7.2 | C | 1,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2007 | 2468 | 15.6 | C | 1,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2008 | 3235 | 31.1 | C | 2,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2009 | 3344 | 3.4 | C | 2,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2010 | 3717 | 11.2 | C | 2,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2011 | 4176 | 12.3 | C | 3,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2012 | 4116 | -1.4 | C | 3,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Menarini Group turnover (private; pharma pure-play)Menarini Group turnover (private; pharma pure-play)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 3200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 美纳里尼 | 2013 | 3324 | -19.2 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 3,324" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 美纳里尼 | 2014 | 3442 | 3.5 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 39 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 3,442" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 美纳里尼 | 2015 | 2836 | -17.6 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 2,836" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 美纳里尼 | 2016 | 2916 | 2.8 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 2,916" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 美纳里尼 | 2017 | 3072 | 5.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 3,072" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 美纳里尼 | 2018 | 3313 | 7.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 3,313" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 美纳里尼 | 2019 | 3233 | -2.4 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Menarini ... 3,233" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 美纳里尼 | 2020 | 3465 | 7.2 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 美纳里尼 | 2021 | 3616 | 4.4 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 美纳里尼 | 2022 | 3621 | 0.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 美纳里尼 | 2023 | 3840 | 6.0 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 美纳里尼 | 2024 | 4006 | 4.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 美纳里尼 | 2025 | 4358 | 8.8 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 美达(Meda) | 2015 | 2139 | – | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 49 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Meda ... 2,139" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 艾伯维 | 2013 | 18790 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 18,790" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 艾伯维 | 2014 | 19879 | 5.8 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 19,879" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 艾伯维 | 2015 | 22724 | 14.3 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 10 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 22,724" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 艾伯维 | 2016 | 25299 | 11.3 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 25,299" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 艾伯维 | 2017 | 27743 | 9.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 27,743" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 艾伯维 | 2018 | 32067 | 15.6 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 32,067" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 艾伯维 | 2019 | 32351 | 0.9 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AbbVie ... 32,351" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 艾伯维 | 2020 | 44341 | 37.1 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 艾伯维 | 2021 | 55041 | 24.1 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 艾伯维 | 2022 | 56179 | 2.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 艾伯维 | 2023 | 52734 | -6.1 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 艾伯维 | 2024 | 54484 | 3.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 艾伯维 | 2025 | 58271 | 7.0 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 艾尔健(Actavis) | 2013 | 7206 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Actavis ... 7,206" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 艾尔健(Actavis) | 2014 | 11130 | 54.5 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 19 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Actavis ... 11,130" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 艾尔建 | 2002 | 1425 | – | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2003 | 1771 | 24.3 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2004 | 2045 | 15.5 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2005 | 2319 | 13.4 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2006 | 2600 | 12.1 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2007 | 3200 | 23.1 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2008 | 3510 | 9.7 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)3700 / (1+5.3%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 艾尔建 | 2009 | 3700 | 5.4 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)allergan 3.7 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 艾尔建 | 2010 | 4000 | 8.1 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2011 | 4400 | 10.0 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)allergan $4.4 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 艾尔建 | 2012 | 5000 | 13.6 | C | phx_est | selected data / segment note | Net sales, specialty pharmaceuticals (medical devices exc...Net sales, specialty pharmaceuticals (medical devices excluded from 2006)Allergan net sales, approximated; device share removed from 2006 Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 艾尔建 | 2013 | 5398 | 8.0 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 5,398" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 艾尔建 | 2014 | 6234 | 15.5 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 28 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 6,234" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 艾尔建 | 2015 | 18403 | 195.2 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 18,403" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 艾尔建 | 2016 | 18597 | 1.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 18,597" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 艾尔建 | 2017 | 14906 | -19.8 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 14,906" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 艾尔建 | 2018 | 14700 | -1.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 20 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 14,700" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 艾尔建 | 2019 | 15153 | 3.1 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 18 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Allergan ... 15,153" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 艾尔建 | 2020 | 4774 | -68.5 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 莫德纳 | 2021 | 19167 | – | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 莫德纳 | 2022 | 18435 | -3.8 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 莫德纳 | 2023 | 6671 | -63.8 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 莫德纳 | 2024 | 3218 | -51.8 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 葛兰素史克 | 2000 | 22889 | – | C | 15,100 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15100 GBP m 2000 = group turnover ~18,079 less Consumer Healthcare ~3,000 |
| 葛兰素史克 | 2001 | 24776 | 8.2 | B | 17,205 GBP m | phx_gsk20f2005+fx_fed_h10 | Financial record, Pharmaceuticals turnover (UK GAAP) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Pharmaceuticals turnover 17205 GBP m (as relayed by search summary of 20-F FY2005) UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself |
| 葛兰素史克 | 2002 | 27036 | 9.1 | B | 17,995 GBP m | phx_gsk20f2005+fx_fed_h10 | Financial record, Pharmaceuticals turnover (UK GAAP) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Pharmaceuticals turnover 17995 GBP m (as relayed by search summary of 20-F FY2005) UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself |
| 葛兰素史克 | 2003 | 29612 | 9.5 | B | 18,114 GBP m | phx_gsk20f2005+fx_fed_h10 | Financial record, Pharmaceuticals turnover (UK GAAP) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Pharmaceuticals turnover 18114 GBP m (as relayed by search summary of 20-F FY2005) UK GAAP; 2003 IFRS equivalent about 18,114; read via search summary, not the table itself; IFRS-restated 2003 = 18,114 |
| 葛兰素史克 | 2004 | 31337 | 5.8 | C | 17,100 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17100 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2005 | 33960 | 8.4 | C | 18,661 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18661 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2006 | 37412 | 10.2 | C | 20,300 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 20300 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2007 | 39433 | 5.4 | C | 19,700 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 19700 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2008 | 39637 | 0.5 | C | 21,400 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21400 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2009 | 38191 | -3.6 | C | 24,400 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24400 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2010 | 37890 | -0.8 | C | 24,500 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24500 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2011 | 38007 | 0.3 | C | 23,700 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 23700 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2012 | 35199 | -7.4 | C | 22,200 GBP m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Pharmaceuticals turnover incl. vaccines (excl. Consumer H...Pharmaceuticals turnover incl. vaccines (excl. Consumer Healthcare)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 22200 GBP m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 葛兰素史克 | 2013 | 33055 | -6.1 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 33,055" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 葛兰素史克 | 2014 | 30302 | -8.3 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 30,302" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 葛兰素史克 | 2015 | 27051 | -10.7 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 27,051" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 葛兰素史克 | 2016 | 27775 | 2.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 27,775" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 葛兰素史克 | 2017 | 28668 | 3.2 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 28,668" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 葛兰素史克 | 2018 | 30645 | 6.9 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 30,645" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 葛兰素史克 | 2019 | 31288 | 2.1 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"GlaxoSmithKline ... 31,288" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 葛兰素史克 | 2020 | 30585 | -2.2 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 葛兰素史克 | 2021 | 33443 | 9.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 葛兰素史克 | 2022 | 38254 | 14.4 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 葛兰素史克 | 2023 | 36758 | -3.9 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 葛兰素史克 | 2024 | 39718 | 8.1 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 葛兰素史克 | 2025 | 42717 | 7.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 诺华 | 2000 | 11000 | – | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 11000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2001 | 12300 | 11.8 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 12300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2002 | 14000 | 13.8 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2003 | 17500 | 25.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2004 | 19800 | 13.1 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 19800 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2005 | 22400 | 13.1 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 22400 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2006 | 27300 | 21.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27300 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2007 | 32646 | 19.6 | B | phx_nov20f2007 | Item 4 principal markets tables | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Pharmaceuticals 24,025 + Sandoz 7,169 + Vaccines and Diagnostics 1,452 = 32,646 (US$ m) Sum of three divisions from the 20-F FY2007 |
|
| 诺华 | 2008 | 35500 | 8.7 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2009 | 38000 | 7.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2010 | 41000 | 7.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 41000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2011 | 44000 | 7.3 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 44000 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2012 | 44500 | 1.1 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics ...Pharmaceuticals + Sandoz/Generics + Vaccines&Diagnostics net sales (excl. consumer, CIBA Vision, Alcon)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 44500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 诺华 | 2013 | 46017 | 3.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 46,017" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 诺华 | 2014 | 46127 | 0.2 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 46,127" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 诺华 | 2015 | 42467 | -7.9 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 42,467" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 诺华 | 2016 | 41554 | -2.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 41,554" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 诺华 | 2017 | 41875 | 0.8 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 41,875" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 诺华 | 2018 | 43481 | 3.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 43,481" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 诺华 | 2019 | 46085 | 6.0 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novartis ... 46,085" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 诺华 | 2020 | 47202 | 2.4 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 诺华 | 2021 | 51128 | 8.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 诺华 | 2022 | 50079 | -2.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 诺华 | 2023 | 52473 | 4.8 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 诺华 | 2024 | 50191 | -4.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 诺华 | 2025 | 54332 | 8.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 诺和诺德 | 2000 | 2218 | – | C | 17,900 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17900 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2001 | 2607 | 17.5 | C | 21,700 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21700 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2002 | 3091 | 18.6 | C | 24,300 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 24300 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2003 | 4020 | 30.1 | C | 26,400 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 26400 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2004 | 4731 | 17.7 | C | 28,300 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28300 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2005 | 5262 | 11.2 | C | 31,500 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 31500 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2006 | 5894 | 12.0 | C | 35,000 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 35000 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2007 | 7121 | 20.8 | C | 38,700 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 38700 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2008 | 8873 | 24.6 | C | 45,000 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 45000 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2009 | 9556 | 7.7 | C | 51,078 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 51078 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2010 | 10833 | 13.4 | C | 60,776 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 60776 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2011 | 12394 | 14.4 | C | 66,346 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 66346 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2012 | 13483 | 8.8 | C | 78,026 DKK m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Total net sales (pure-play pharma)Total net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 78026 DKK m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 诺和诺德 | 2013 | 14886 | 10.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 14,886" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 诺和诺德 | 2014 | 15825 | 6.3 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 15,825" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 诺和诺德 | 2015 | 16054 | 1.4 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 14 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 16,054" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 诺和诺德 | 2016 | 16610 | 3.5 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 17 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 16,610" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 诺和诺德 | 2017 | 16971 | 2.2 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 16,971" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 诺和诺德 | 2018 | 17726 | 4.4 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 15 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 17,726" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 诺和诺德 | 2019 | 18296 | 3.2 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 16 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Novo Nordisk ... 18,296" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 诺和诺德 | 2020 | 19444 | 6.3 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 诺和诺德 | 2021 | 22417 | 15.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 诺和诺德 | 2022 | 25384 | 13.2 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 诺和诺德 | 2023 | 33722 | 32.8 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 诺和诺德 | 2024 | 42122 | 24.9 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 诺和诺德 | 2025 | 46801 | 11.1 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 费森尤斯 | 2013 | 3604 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius ... 3,604" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 费森尤斯 | 2014 | 3707 | 2.9 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 37 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius ... 3,707" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 费森尤斯 | 2015 | 3709 | 0.1 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius ... 3,709" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 费森尤斯 | 2016 | 3753 | 1.2 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 36 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius ... 3,753" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 费森尤斯 | 2017 | 4070 | 8.4 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius ... 4,070" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 费森尤斯 | 2018 | 4328 | 6.3 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 34 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius ... 4,328" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 费森尤斯 | 2019 | 4224 | -2.4 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 38 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Fresenius Kabi ... 4,224" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 费森尤斯 | 2020 | 4221 | -0.1 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 费森尤斯 | 2021 | 4224 | 0.1 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 费森尤斯 | 2022 | 4342 | 2.8 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 费森尤斯 | 2023 | 4538 | 4.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 费森尤斯 | 2024 | 4810 | 6.0 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 费森尤斯 | 2025 | 5206 | 8.2 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 赛诺菲 | 2004 | 17787 | – | C | 14,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 14300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2005 | 33606 | 88.9 | C | 27,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2006 | 35544 | 5.8 | C | 28,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2007 | 38385 | 8.0 | C | 28,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 28000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2008 | 39702 | 3.4 | C | 27,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2009 | 40822 | 2.8 | C | 29,300 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29300 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2010 | 40359 | -1.1 | C | 30,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 30400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2011 | 46494 | 15.2 | C | 33,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2012 | 44894 | -3.4 | C | 34,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. ...Sanofi-aventis / Sanofi pharmaceuticals net sales (excl. Animal Health/Merial where separable)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 34900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲 | 2013 | 37701 | -16.0 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 37,701" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 赛诺菲 | 2014 | 38223 | 1.4 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 38,223" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 赛诺菲 | 2015 | 34896 | -8.7 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 34,896" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 赛诺菲 | 2016 | 34174 | -2.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 34,174" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 赛诺菲 | 2017 | 34078 | -0.3 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 34,078" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 赛诺菲 | 2018 | 35121 | 3.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 6 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 35,121" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 赛诺菲 | 2019 | 34924 | -0.6 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 7 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Sanofi ... 34,924" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 赛诺菲 | 2020 | 35802 | 2.5 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 赛诺菲 | 2021 | 38934 | 8.7 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 赛诺菲 | 2022 | 40353 | 3.6 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 赛诺菲 | 2023 | 40805 | 1.1 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 赛诺菲 | 2024 | 44243 | 8.4 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 赛诺菲 | 2025 | 48971 | 10.7 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 赛诺菲-圣德拉堡 | 2000 | 4155 | – | C | 4,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 4500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲-圣德拉堡 | 2001 | 4836 | 16.4 | C | 5,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲-圣德拉堡 | 2002 | 6145 | 27.1 | C | 6,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赛诺菲-圣德拉堡 | 2003 | 8375 | 36.3 | C | 7,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Sanofi-Synthelabo net sales (pure-play pharma)Sanofi-Synthelabo net sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 赫力昂 | 2025 | 3599 | – | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 赫士睿 | 2013 | 2759 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 43 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Hospira ... 2,759" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 赫士睿 | 2014 | 3035 | 10.0 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Hospira ... 3,035" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 赫士睿 | 2015 | 2131 | -29.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Hospira ... 2,131" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 辉凌 | 2016 | 2134 | – | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ferring ... 2,134" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 辉凌 | 2017 | 2243 | 5.1 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ferring ... 2,243" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 辉凌 | 2018 | 2461 | 9.7 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Ferring ... 2,461" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 辉瑞 | 2000 | 24400 | – | C | phx_est | selected data / segment note | Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 辉瑞 | 2001 | 26800 | 9.8 | C | phx_est | selected data / segment note | Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 辉瑞 | 2002 | 27100 | 1.1 | C | phx_est | selected data / segment note | Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 辉瑞 | 2003 | 39425 | 45.5 | B | phx_sec_pfe2005 | Financial Review, Human Health revenue table p.12 | Human Health segment revenues (includes Pharmacia from Ap...Human Health segment revenues (includes Pharmacia from Apr 2003)Human Health 2003 39,425 (total revenues 44,736) Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K) |
|
| 辉瑞 | 2004 | 46133 | 17.0 | B | phx_sec_pfe2005 | Financial Review, Human Health revenue table p.12 | Human Health segment revenuesHuman Health segment revenuesHuman Health 2004 46,133 (total revenues 52,516) Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K) |
|
| 辉瑞 | 2005 | 44284 | -4.0 | B | phx_sec_pfe2005 | Financial Review, Human Health revenue table p.12 | Human Health segment revenuesHuman Health segment revenuesHuman Health 2005 44,284 (total revenues 51,298) Pfizer 2005 Financial Report (Exhibit 13 to FY2005 10-K) |
|
| 辉瑞 | 2006 | 45100 | 1.8 | C | phx_est | selected data / segment note | Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 辉瑞 | 2007 | 44400 | -1.6 | C | phx_est | selected data / segment note | Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 辉瑞 | 2008 | 44210 | -0.4 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)45400 / (1+2.7%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 辉瑞 | 2009 | 45400 | 2.7 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)pfizer 45.4 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Pfizer excludes Wyeth, which is its own entity until absorbed |
|
| 辉瑞 | 2010 | 58500 | 28.9 | B | phx_pe2011 | Pharm Exec 50 (2011): Pfizer 2010 Rx sales | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)"grew from $45.4 billion in Rx sales to $58.5 billion" 2010 includes Wyeth; read from a search-result summary of the 12th Pharm Exec 50 (page not retrievable) |
|
| 辉瑞 | 2011 | 57700 | -1.4 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)pfizer $57.7 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 辉瑞 | 2012 | 48000 | -16.8 | C | phx_est | selected data / segment note | Pharmaceutical segment, approx. (total revenues less cons...Pharmaceutical segment, approx. (total revenues less consumer, animal health, other); 2000-02 incl. Warner-Lambert (pooled)Pfizer total revenues 29.6/32.3/32.4 bn (2000-02) less consumer ~3, animal ~1.8, other Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 辉瑞 | 2013 | 45011 | -6.2 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 45,011" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 辉瑞 | 2014 | 44514 | -1.1 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 2 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 44,514" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 辉瑞 | 2015 | 43112 | -3.1 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 43,112" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 辉瑞 | 2016 | 45906 | 6.5 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 45,906" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 辉瑞 | 2017 | 45345 | -1.2 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 45,345" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 辉瑞 | 2018 | 45302 | -0.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 1 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 45,302" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 辉瑞 | 2019 | 43662 | -3.6 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 3 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Pfizer ... 43,662" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 辉瑞 | 2020 | 35608 | -18.4 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 辉瑞 | 2021 | 72043 | 102.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 辉瑞 | 2022 | 91303 | 26.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 辉瑞 | 2023 | 48218 | -47.2 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 辉瑞 | 2024 | 51953 | 7.7 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 辉瑞 | 2025 | 49909 | -3.9 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 迈蓝 | 2008 | 4310 | – | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)4800 / (1+11.4%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 迈蓝 | 2009 | 4800 | 11.4 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)mylan 4.8 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 迈蓝 | 2010 | 5450 | 13.5 | C | phx_est | selected data / segment note | Total revenues (generics)Total revenues (generics)Mylan total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 迈蓝 | 2011 | 5500 | 0.9 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)mylan $5.5 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 迈蓝 | 2012 | 6800 | 23.6 | C | phx_est | selected data / segment note | Total revenues (generics)Total revenues (generics)Mylan total revenues Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 迈蓝 | 2013 | 6772 | -0.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 6,772" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 迈蓝 | 2014 | 7585 | 12.0 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 7,585" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 迈蓝 | 2015 | 9291 | 22.5 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 9,291" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 迈蓝 | 2016 | 10839 | 16.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 10,839" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 迈蓝 | 2017 | 11454 | 5.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 11,454" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 迈蓝 | 2018 | 11144 | -2.7 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 22 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 11,144" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 迈蓝 | 2019 | 11200 | 0.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 21 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mylan ... 11,200" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 远藤国际 | 2014 | 2238 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Endo ... 2,238" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 远藤国际 | 2015 | 2856 | 27.6 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Endo ... 2,856" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 远藤国际 | 2016 | 4010 | 40.4 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Endo ... 4,010" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 远藤国际 | 2017 | 3469 | -13.5 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Endo ... 3,469" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 远藤国际 | 2018 | 2947 | -15.0 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Endo ... 2,947" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 远藤国际 | 2019 | 2887 | -2.0 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Endo International ... 2,887" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 远藤国际 | 2020 | 2897 | 0.3 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 远藤国际 | 2021 | 2990 | 3.2 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 阿拉宾度制药 | 2019 | 2787 | – | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 50 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Aurobindo Pharma ... 2,787" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 阿拉宾度制药 | 2020 | 3000 | 7.6 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 阿拉宾度制药 | 2021 | 3159 | 5.3 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 阿斯利康 | 2000 | 15500 | – | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 15500 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2001 | 16480 | 6.3 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 16480 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2002 | 17841 | 8.3 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 17841 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2003 | 18849 | 5.6 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 18849 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2004 | 21426 | 13.7 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 21426 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2005 | 23950 | 11.8 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 23950 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2006 | 26475 | 10.5 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 26475 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2007 | 29559 | 11.6 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 29559 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2008 | 31601 | 6.9 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 31601 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2009 | 32804 | 3.8 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 32804 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2010 | 33269 | 1.4 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33269 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2011 | 33591 | 1.0 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 33591 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2012 | 27973 | -16.7 | C | phx_ar_recall | five/ten-year summary of the annual report (not located) | Total sales (pure-play pharma)Total sales (pure-play pharma)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 27973 USD m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
|
| 阿斯利康 | 2013 | 24523 | -12.3 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 24,523" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 阿斯利康 | 2014 | 25694 | 4.8 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 8 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 25,694" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 阿斯利康 | 2015 | 23264 | -9.5 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 9 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 23,264" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 阿斯利康 | 2016 | 20967 | -9.9 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 20,967" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 阿斯利康 | 2017 | 19782 | -5.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 19,782" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 阿斯利康 | 2018 | 20671 | 4.5 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 12 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 20,671" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 阿斯利康 | 2019 | 23207 | 12.3 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 11 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"AstraZeneca ... 23,207" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 阿斯利康 | 2020 | 25518 | 10.0 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 阿斯利康 | 2021 | 36131 | 41.6 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 阿斯利康 | 2022 | 42998 | 19.0 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 阿斯利康 | 2023 | 43790 | 1.8 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 阿斯利康 | 2024 | 50946 | 16.3 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 阿斯利康 | 2025 | 55038 | 8.0 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 阿斯本制药 | 2013 | 2710 | – | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Aspen ... 2,710" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 阿斯本制药 | 2014 | 3066 | 13.1 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 41 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Aspen ... 3,066" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 阿斯本制药 | 2015 | 2586 | -15.7 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Aspen ... 2,586" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 阿斯本制药 | 2016 | 2403 | -7.1 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 47 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Aspen ... 2,403" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 阿斯本制药 | 2017 | 2591 | 7.8 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 44 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Aspen ... 2,591" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 雀巢健康科学 | 2015 | 2431 | – | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Nestle ... 2,431" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 雅培 | 2000 | 7300 | – | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2001 | 7900 | 8.2 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2002 | 8500 | 7.6 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2003 | 9300 | 9.4 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2004 | 10000 | 7.5 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2005 | 10800 | 8.0 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2006 | 11600 | 7.4 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2007 | 12800 | 10.3 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2008 | 14300 | 11.7 | C | phx_est | Segment note | Pharmaceutical Products segment (est.)Pharmaceutical Products segment (est.)Pharm Exec 2009 15.6 bn; its change column (-6.7%) would imply 16.7 bn for 2008, which does not fit the 10-K segment (about 14 bn) Estimate from memory of the segment figure; the Pharm Exec derived 2008 value is not used because FX/perimeter makes it inconsistent with the segment |
|
| 雅培 | 2009 | 15600 | 9.1 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)abbott 15.6 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn |
|
| 雅培 | 2010 | 19100 | 22.4 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2011 | 22400 | 17.3 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)abbott $22.4 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 雅培 | 2012 | 22900 | 2.2 | C | phx_est | selected data / segment note | Pharmaceutical Products segment (incl. the business later...Pharmaceutical Products segment (incl. the business later spun off as AbbVie; from 2010 incl. Solvay / established pharma)Abbott 10-K segment note, approximated Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 雅培 | 2013 | 4974 | -78.3 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 30 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott ... 4,974" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 雅培 | 2014 | 5101 | 2.6 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 31 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott ... 5,101" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 雅培 | 2015 | 3720 | -27.1 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott ... 3,720" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 雅培 | 2016 | 3859 | 3.7 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott ... 3,859" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 雅培 | 2017 | 4287 | 11.1 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott ... 4,287" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 雅培 | 2018 | 4422 | 3.1 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 33 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott ... 4,422" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 雅培 | 2019 | 4486 | 1.4 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 35 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Abbott Laboratories ... 4,486" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 雅培 | 2020 | 4486 | 0.0 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 雅培 | 2021 | 4692 | 4.6 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 雅培 | 2022 | 4885 | 4.1 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 雅培 | 2023 | 5039 | 3.2 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 雅培 | 2024 | 5166 | 2.5 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 雅培 | 2025 | 5508 | 6.6 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 雪兰诺 | 2000 | 770 | – | C | 1,300 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1300 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 雪兰诺 | 2001 | 949 | 23.2 | C | 1,600 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1600 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 雪兰诺 | 2002 | 1160 | 22.3 | C | 1,800 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1800 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 雪兰诺 | 2003 | 1637 | 41.1 | C | 2,200 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2200 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 雪兰诺 | 2004 | 1933 | 18.1 | C | 2,400 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 雪兰诺 | 2005 | 2009 | 3.9 | C | 2,500 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2500 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 雪兰诺 | 2006 | 2155 | 7.3 | C | 2,700 CHF m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Serono SA total revenues (pure-play biotech/pharma; acqui...Serono SA total revenues (pure-play biotech/pharma; acquired by Merck KGaA 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 CHF m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 马林克罗 | 2014 | 2310 | – | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 46 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mallinckrodt ... 2,310" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 马林克罗 | 2015 | 2976 | 28.8 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 40 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mallinckrodt ... 2,976" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 马林克罗 | 2016 | 2918 | -1.9 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mallinckrodt ... 2,918" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 马林克罗 | 2017 | 3141 | 7.6 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 42 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mallinckrodt ... 3,141" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 马林克罗 | 2018 | 2543 | -19.0 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Mallinckrodt ... 2,543" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 鲁宾 | 2016 | 2490 | – | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 45 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Lupin ... 2,490" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 鲁宾 | 2017 | 2344 | -5.9 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 48 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Lupin ... 2,344" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 默克集团 | 2000 | 1754 | – | C | 1,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 1900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2001 | 1881 | 7.2 | C | 2,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2002 | 2269 | 20.6 | C | 2,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2003 | 2716 | 19.7 | C | 2,400 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2400 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2004 | 3358 | 23.7 | C | 2,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2005 | 3485 | 3.8 | C | 2,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2006 | 3642 | 4.5 | C | 2,900 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 2900 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2007 | 7814 | 114.5 | C | 5,700 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 5700 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2008 | 8823 | 12.9 | C | 6,000 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6000 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2009 | 8499 | -3.7 | C | 6,100 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6100 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2010 | 9028 | 6.2 | C | 6,800 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 6800 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2011 | 10023 | 11.0 | C | 7,200 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7200 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2012 | 9648 | -3.7 | C | 7,500 EUR m | phx_ar_recall+fx_fed_h10 | five/ten-year summary of the annual report (not located) | Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono...Merck KGaA Pharmaceuticals / Ethicals (incl. Merck Serono from 2007)Recalled from company annual-report five/ten-year summaries; figure not re-opened in this session; 7500 EUR m Estimate (grade C): rounded from memory of the company's reported segment/group figures. Check against the annual report summary before publication. |
| 默克集团 | 2013 | 7913 | -18.0 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 7,913" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 默克集团 | 2014 | 7683 | -2.9 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 23 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 7,683" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 默克集团 | 2015 | 7693 | 0.1 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 24 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 7,693" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 默克集团 | 2016 | 6633 | -13.8 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 6,633" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 默克集团 | 2017 | 6880 | 3.7 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 6,880" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 默克集团 | 2018 | 7001 | 1.8 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 27 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 7,001" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 默克集团 | 2019 | 7516 | 7.4 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 25 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck KGaA ... 7,516" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 默克集团 | 2020 | 7579 | 0.8 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 默克集团 | 2021 | 8392 | 10.7 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 默克集团 | 2022 | 8366 | -0.3 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 默克集团 | 2023 | 8711 | 4.1 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 默克集团 | 2024 | 9148 | 5.0 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 默克集团 | 2025 | 9728 | 6.3 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 默沙东 | 2000 | 19700 | – | C | phx_est | selected data / segment note | Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-MedcoMerck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 默沙东 | 2001 | 21200 | 7.6 | C | phx_est | selected data / segment note | Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-MedcoMerck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 默沙东 | 2002 | 21446 | 1.2 | B | phx_sec_mrk2006 | FY2006 10-K Item 6 selected financial data | Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)Sales 21,445.8 Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8) |
|
| 默沙东 | 2003 | 22486 | 4.8 | B | phx_sec_mrk2006 | FY2005 Exhibit 13 income statement | Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)Sales 22,485.9 Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8) |
|
| 默沙东 | 2004 | 22939 | 2.0 | B | phx_sec_mrk2006 | FY2005 Exhibit 13 income statement | Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)Sales 22,938.6 Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8) |
|
| 默沙东 | 2005 | 22012 | -4.0 | B | phx_sec_mrk2006 | FY2006 10-K Item 1 product sales table | Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)Sales 22,011.9 Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8) |
|
| 默沙东 | 2006 | 22636 | 2.8 | B | phx_sec_mrk2006 | FY2006 10-K Item 1 product sales table | Total sales (Merck Rx incl. vaccines; Medco spun off Aug ...Total sales (Merck Rx incl. vaccines; Medco spun off Aug 2003, excluded)Sales 22,636.0 Merck sales without Medco; later restatements differ by <1% (2004: 22,938.6 vs 22,972.8) |
|
| 默沙东 | 2007 | 24200 | 6.9 | C | phx_est | selected data / segment note | Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-MedcoMerck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 默沙东 | 2008 | 23570 | -2.6 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 sales and change-from-2008 columns | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)25200 / (1+6.9%) 2008 = 2009 Rx sales divided by the table change column (FX effects included, the source warns); Merck 2008 excludes Schering-Plough |
|
| 默沙东 | 2009 | 25200 | 6.9 | B | phx_pe2010 | Pharm Exec 50 (May 2010), 2009 Rx sales table | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)merck 25.2 (US$ bn) Pharm Exec 50 2010 edition, 2009 sales rounded to US$ 0.1 bn; Merck includes Schering-Plough from Nov 2009 |
|
| 默沙东 | 2010 | 39500 | 56.7 | C | phx_est | selected data / segment note | Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-MedcoMerck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 默沙东 | 2011 | 41300 | 4.6 | B | phx_pe2012 | Pharm Exec 50 (June 2012), 2011 Rx sales company profiles | Prescription drug sales (Pharm Exec 50 basis)Prescription drug sales (Pharm Exec 50 basis)merck $41.3 bn Pharm Exec 50 2012 edition, 2011 sales rounded to US$ 0.1 bn |
|
| 默沙东 | 2012 | 40500 | -1.9 | C | phx_est | selected data / segment note | Pharmaceutical segment / total sales ex-MedcoPharmaceutical segment / total sales ex-MedcoMerck sales ex-Medco; 2010/2012 pharmaceutical segment = total less animal health, consumer and other (Schering-Plough incl. from Nov 2009) Estimate: approximated from the company reported pharma segment or sales (filings not re-read; about +-5%); verify against the 10-K |
|
| 默沙东 | 2013 | 37519 | -7.4 | B | phx_pe2014 | Pharm Exec 50 (June 2014), table '2013 Rx Sales (USD in mln)', image Top-50-Pharma-Cos-2014-Page-1..5, rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 37,519" (US$ m) Pharm Exec 50 2014 edition; Japanese companies: FY ending March 2013 per the table's footnote |
|
| 默沙东 | 2014 | 36607 | -2.4 | B | phx_pe2015 | Pharm Exec 50 (June 2015), table '2014 Rx Sales (USD in mln)', images Table 1-10 NEW / 11-20 / 21-30 / 31-40 / 41-50, rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 36,607" (US$ m) Pharm Exec 50 2015 edition; Japanese companies: FY ending March 2015 per footnote |
|
| 默沙东 | 2015 | 35244 | -3.7 | B | phx_pe2016 | Pharm Exec 50 (June 2016), table '2015 Rx Sales (USD in mln)' (also topforeignstocks.com 2016/11/11 reprint), rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 35,244" (US$ m) Pharm Exec 50 2016 edition; Japanese companies: FY ending March 2016 per footnote |
|
| 默沙东 | 2016 | 35563 | 0.9 | B | phx_pe2017 | Pharm Exec 50 (June 2017), table '2016 Rx Sales (USD in mln)', images 'Pharma 50 1-10' ... '41-50', rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 35,563" (US$ m) Pharm Exec 50 2017 edition; Japanese companies: FY ending March 2017 per footnote |
|
| 默沙东 | 2017 | 35370 | -0.5 | B | phx_pe2018 | Pharm Exec 50 (June 2018), table '2017 Rx Sales (USD in mln)', images Page-1..5, rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 35,370" (US$ m) Pharm Exec 50 2018 edition; Japanese companies: FY ending March 2018 per footnote |
|
| 默沙东 | 2018 | 37353 | 5.6 | B | phx_pe2019 | 图表1:2019年全球TOP 50制药企业 (Pharm Exec 50 2019 edition reprinted by Qianzhan), column 处方药销售额 (亿美元), rank 5 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 37,353" (US$ m) Pharm Exec 50 2019 edition (2018 sales) via Qianzhan reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2019 as in other editions |
|
| 默沙东 | 2019 | 40903 | 9.5 | B | phx_pe2020 | 2020年全球TOP50制药企业排行榜 table, column 2019年度销售额 (亿美元), rank 4 | Prescription drug sales (Pharm Exec 50 / EvaluatePharma)Prescription drug sales (Pharm Exec 50 / EvaluatePharma)"Merck & Co. ... 40,903" (US$ m) Pharm Exec 50 2020 edition (2019 sales) via Maigoo reprint, US$ 100 m units converted to US$ m; Japanese FY assumed ending March 2020 |
|
| 默沙东 | 2020 | 41435 | 1.3 | B | pharmexec_2021 | Pharm Exec 50, 2021 edition (2020 prescription sales)Pharm Exec 50, 2021 edition (2020 prescription sales)The full table, with each company’s home; an edition ranks the previous year’s sales. Total of the 50: US$728.9 billion. |
||
| 默沙东 | 2021 | 43259 | 4.4 | B | pharmexec_2022 | Pharm Exec 50, 2022 edition (2021 prescription sales)Pharm Exec 50, 2022 edition (2021 prescription sales)Total of the 50: US$855.9 billion. |
||
| 默沙东 | 2022 | 49627 | 14.7 | B | pharmexec_2023 | Pharm Exec 50, 2023 edition (2022 prescription sales)Pharm Exec 50, 2023 edition (2022 prescription sales)Total of the 50: US$894.1 billion; the reprint’s line for Chugai is garbled, so US$4.0 billion stays unattributed. |
||
| 默沙东 | 2023 | 50846 | 2.5 | B | pharmexec_2024 | Pharm Exec 50, 2024 edition (2023 prescription sales)Pharm Exec 50, 2024 edition (2023 prescription sales)Total of the 50: US$868.2 billion. |
||
| 默沙东 | 2024 | 54314 | 6.8 | B | pharmexec_2025 | Pharm Exec 50, 2025 edition (2024 prescription sales)Pharm Exec 50, 2025 edition (2024 prescription sales)Total of the 50: US$934.2 billion. |
||
| 默沙东 | 2025 | 54685 | 0.7 | B | pharmexec_2026 | Pharm Exec 50, 2026 edition (2025 prescription sales)Pharm Exec 50, 2026 edition (2025 prescription sales)Total of the 50: US$1,008.3 billion. BeiGene appears as BeOne Medicines, based in Switzerland since its move to Basel. |
||
| 中外制药 | FY2001 | – | – | uncertain | 203000 JPY | https://the-shashi.com/tse/4519/finan... | Fiscal year ended March until 2002, then December after t...Fiscal year ended March until 2002, then December after the Roche tie-up (the 9-month transition period to Dec 2002, 237,300, is left out). FY2000 and FY2001 are both 203,000 in the source: suspicious, so FY2001 is kept out of the chart. Aggregator (the-shashi.com) quoting the securities reports; fiscal year ends in March of the year named. |
|
| 中国生物制药 | 2008 | – | – | uncertain | 2282 HKD | https://www1.hkexnews.hk/listedco/lis... | Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain. |
|
| 中国生物制药 | 2009 | – | – | uncertain | 3244 HKD | https://www1.hkexnews.hk/listedco/lis... | Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain. |
|
| 中国生物制药 | 2010 | – | – | uncertain | 4086 HKD | https://www1.hkexnews.hk/listedco/lis... | Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain. |
|
| 中国生物制药 | 2011 | – | – | uncertain | 5782 HKD | https://www1.hkexnews.hk/listedco/lis... | Currency (HKD vs RMB) taken from a search summary, not ch...Currency (HKD vs RMB) taken from a search summary, not checked in the document; left uncertain. |
|
| 山之内制药 | FY1999/00 | – | – | missing | – | Yamanouchi sales for FY1999/00 and FY2000/01 not found in...Yamanouchi sales for FY1999/00 and FY2000/01 not found in the sources reached. |
||
| 山之内制药 | FY2000/01 | – | – | missing | – | Yamanouchi sales for FY1999/00 and FY2000/01 not found in...Yamanouchi sales for FY1999/00 and FY2000/01 not found in the sources reached. |
||
| 藤泽药品工业 | FY1999/00 | – | – | missing | – | Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached. |
||
| 藤泽药品工业 | FY2000/01 | – | – | missing | – | Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached. |
||
| 藤泽药品工业 | FY2001/02 | – | – | missing | – | Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached. |
||
| 藤泽药品工业 | FY2002/03 | – | – | missing | – | Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached. |
||
| 藤泽药品工业 | FY2003/04 | – | – | missing | – | Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached. |
||
| 藤泽药品工业 | FY2004/05 | – | – | missing | – | Fujisawa Pharmaceutical consolidated sales not found in t...Fujisawa Pharmaceutical consolidated sales not found in the sources reached. |
||
| 三共 | FY1999/00 | – | – | missing | – | Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation. |
||
| 三共 | FY2000/01 | – | – | missing | – | Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation. |
||
| 三共 | FY2001/02 | – | – | missing | – | Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation. |
||
| 三共 | FY2002/03 | – | – | missing | – | Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation. |
||
| 三共 | FY2003/04 | – | – | missing | – | Sankyo pharma sales not found except the FY2004/05 deriva...Sankyo pharma sales not found except the FY2004/05 derivation. |
||
| 第一制药(日本) | FY1999/00 | – | – | missing | – | Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached. |
||
| 第一制药(日本) | FY2000/01 | – | – | missing | – | Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached. |
||
| 第一制药(日本) | FY2001/02 | – | – | missing | – | Selected Financial Data section of the 20-F not reached.Selected Financial Data section of the 20-F not reached. |
||
| 盐野义制药 | FY1999/00 | – | – | missing | – | Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used. |
||
| 盐野义制药 | FY2000/01 | – | – | missing | – | Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used. |
||
| 盐野义制药 | FY2001/02 | – | – | missing | – | Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used. |
||
| 盐野义制药 | FY2002/03 | – | – | missing | – | Aggregator values for FY2000-2003 (412,600 / 420,100 / 28...Aggregator values for FY2000-2003 (412,600 / 420,100 / 285,200) are far above Shionogi's ~200 bn and not credible; not used. |
||
| 小野制药 | FY1999/00 | – | – | missing | – | Not found.Not found. |
||
| 小野制药 | FY2000/01 | – | – | missing | – | Not found.Not found. |
||
| 大冢 | FY1999/00 | – | – | missing | – | Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable. |
||
| 大冢 | FY2000/01 | – | – | missing | – | Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable. |
||
| 大冢 | FY2001/02 | – | – | missing | – | Pre-2003 table is non-consolidated and not comparable.Pre-2003 table is non-consolidated and not comparable. |
||
| 三菱制药 | FY1999/00 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 三菱制药 | FY2000/01 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 三菱制药 | FY2001/02 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 三菱制药 | FY2002/03 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 三菱制药 | FY2003/04 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 三菱制药 | FY2004/05 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 三菱制药 | FY2005/06 | – | – | missing | – | Mitsubishi Pharma sales not found in the sources reached ...Mitsubishi Pharma sales not found in the sources reached (about 230 bn yen in FY2005/06 by inference). |
||
| 田边制药 | FY1999/00 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边制药 | FY2000/01 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边制药 | FY2001/02 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边制药 | FY2002/03 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边制药 | FY2003/04 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边制药 | FY2004/05 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边制药 | FY2005/06 | – | – | missing | – | Tanabe Seiyaku sales not found in the sources reached (pr...Tanabe Seiyaku sales not found in the sources reached (prescription revenue 153.0 bn yen quoted for 2005). |
||
| 田边三菱制药 | FY2006/07 | – | – | missing | – | FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached. |
||
| 田边三菱制药 | FY2007/08 | – | – | missing | – | FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached. |
||
| 田边三菱制药 | FY2008/09 | – | – | missing | – | FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached. |
||
| 田边三菱制药 | FY2009/10 | – | – | missing | – | FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached. |
||
| 田边三菱制药 | FY2010/11 | – | – | missing | – | FY2007-FY2010 not found in the sources reached.FY2007-FY2010 not found in the sources reached. |
||
| 协和麒麟 | 2000 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2001 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2002 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2003 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2004 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2005 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2006 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2007 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2008 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 协和麒麟 | 2009 | – | – | missing | – | Kyowa Hakko pharma share of group sales (chemicals, bio, ...Kyowa Hakko pharma share of group sales (chemicals, bio, food) not found. |
||
| 瑞迪博士实验室 | FY1999/00 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2000/01 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2001/02 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2002/03 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2003/04 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2004/05 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2005/06 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 瑞迪博士实验室 | FY2006/07 | – | – | missing | – | Not found in the sources reached.Not found in the sources reached. |
||
| 兰伯西 | 2000 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2001 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2002 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2003 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2004 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2005 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2006 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 兰伯西 | 2007 | – | – | missing | – | Consolidated sales not found (AR2010 ten-year table is st...Consolidated sales not found (AR2010 ten-year table is standalone only). |
||
| 太阳制药 | FY1999/00 | – | – | missing | – | Not found (FY2012: 2012-13 annual report ten-year table n...Not found (FY2012: 2012-13 annual report ten-year table not reached). |
||
| 太阳制药 | FY2000/01 | – | – | missing | – | Not found (FY2012: 2012-13 annual report ten-year table n...Not found (FY2012: 2012-13 annual report ten-year table not reached). |
||
| 太阳制药 | FY2011/12 | – | – | missing | – | Not found (FY2012: 2012-13 annual report ten-year table n...Not found (FY2012: 2012-13 annual report ten-year table not reached). |
||
| 恒瑞医药 | 2000 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2001 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2002 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2003 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2004 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2005 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2006 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2007 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2008 | – | – | missing | – | Not found.Not found. |
||
| 恒瑞医药 | 2009 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2000 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2001 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2002 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2003 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2004 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2005 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2006 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2007 | – | – | missing | – | Not found.Not found. |
||
| 中国生物制药 | 2012 | – | – | missing | – | Not found.Not found. |
||
| 西普拉 | FY1999/00 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2000/01 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2001/02 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2002/03 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2003/04 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2004/05 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2005/06 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2006/07 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2007/08 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2008/09 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2009/10 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2010/11 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 西普拉 | FY2011/12 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY1999/00 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2000/01 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2001/02 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2002/03 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2003/04 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2004/05 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2005/06 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2006/07 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2007/08 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2008/09 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2009/10 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2010/11 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 鲁宾 | FY2011/12 | – | – | missing | – | Not searched within the call budget.Not searched within the call budget. |
||
| 国药集团 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 国药集团 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 云南白药 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 石药集团 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华东医药 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 天士力 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 哈药集团 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 华北制药 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2000 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2001 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2002 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2003 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2004 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2005 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2006 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2007 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2008 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2009 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2010 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2011 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| CJ第一制糖 | 2012 | – | – | missing | – | Not searched within the call budget; Chinese and Korean p...Not searched within the call budget; Chinese and Korean pharmas 2000-2012 still open. |
||
| 渤健 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2010 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 渤健 | 2012 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 健赞 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2010 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 森林实验室 | 2012 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2008 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2009 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 金制药 | 2010 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2010 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 沃森制药 | 2012 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 迈蓝 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2004 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2005 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2006 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2007 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2010 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 百特 | 2012 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 艾尔建 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 艾尔建 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 吉利德科学 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 吉利德科学 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 吉利德科学 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 新基 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 新基 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 新基 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 基因泰克 | 2000 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 基因泰克 | 2001 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 基因泰克 | 2002 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 基因泰克 | 2003 | – | – | missing | – | No pharma-basis figure found within the research budget; ...No pharma-basis figure found within the research budget; fill from the 10-K ten-year table |
||
| 国药集团 | 2013 | – | – | missing | https://www1.hkexnews.hk/listedco/lis... | Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found. |
||
| 国药集团 | 2014 | – | – | missing | https://www1.hkexnews.hk/listedco/lis... | Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found. |
||
| 国药集团 | 2015 | – | – | missing | https://www1.hkexnews.hk/listedco/lis... | Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found. |
||
| 国药集团 | 2016 | – | – | missing | https://www1.hkexnews.hk/listedco/lis... | Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found. |
||
| 国药集团 | 2017 | – | – | missing | https://www1.hkexnews.hk/listedco/lis... | Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013...Sinopharm Group revenue (RMB 135.8 bn 2012, 166.9 bn 2013, 200.1 bn 2014) is about 95% distribution and retail and is deliberately not counted; manufacturing sits inside 'other business' without a separate figure. Parent CNPGC industry arm not found. |